Tsütokiinide ja neuroendokriinse süsteemi osalemine vitiliigo patogeneesis by Reimann, Ene
E
N
E
 R
E
IM
A
N
N
 
D
escription of the cytokines and cutaneous neuroendocrine system
 in the developm
ent of vitiligoTartu 2012
ISSN 1736–2792
ISBN 978–9949–32–155–1
DISSERTATIONES 
NEUROSCIENTIAE
UNIVERSITATIS 
TARTUENSIS
17
ENE REIMANN
Description of the cytokines and 
cutaneous neuroendocrine system 
in the development of vitiligo
DISSERTATIONES NEUROSCIENTIAE UNIVERSITATIS TARTUENSIS 
17 
DISSERTATIONES NEUROSCIENTIAE UNIVERSITATIS TARTUENSIS 
17 
 
 
 
 
 
 
 
ENE REIMANN 
 
 
Description of the cytokines and  
cutaneous neuroendocrine system  
in the development of vitiligo 
Department of Physiology, University of Tartu, Tartu, Estonia 
 
The dissertation was accepted for the commencement of the degree of Doctor 
Philosophiae in neurosciences on September 24, 2012 by the Council of the 
Commencement of Doctoral Degrees in Neurosciences 
 
 
Supervisors: Sulev Kõks, MD, PhD, Professor, Department of Physiology, 
University of Tartu 
Külli Kingo, MD, PhD, Professor, Department of Dermatology 
and Venereology, University of Tartu 
 
Reviewers: Pärt Peterson, PhD, Professor, Department of Molecular 
Pathology, University of Tartu 
Maido Remm, PhD, Professor, Department of Bioinformatics, 
University of Tartu 
 
Opponent:  Päivi Saavalainen, PhD, Docent, Department of Medical Genetics 
and Research Program for Molecular Medicine, University of 
Helsinki, Finland 
 
Commencement: December 7, 2012 
 
This research was supported by the European Regional Development Fund.  
Publication of this dissertation is granted by the University of Tartu 
 
 
 
 
 
 
 
 
ISSN 1736–2792 
ISBN 978–9949–32–155–1 (print)  
ISBN 978–9949–32–156–8 (pdf) 
 
 
Copyright: Ene Reimann, 2012 
 
University of Tartu Press 
www.tyk.ee 
Order No. 518 
5 
CONTENTS 
LIST OF ORIGINAL PUBLICATIONS .......................................................  7 
ABBREVIATIONS ........................................................................................  8 
1.  INTRODUCTION .....................................................................................  11 
2.  REVIEW OF LITERATURE ....................................................................  13 
2.1.  Skin as a neuroimmunoendocrine organ ............................................  13 
2.1.1. Neuroendocrine axes: cutaneous HPA axis .............................  14 
2.2.  Vitiligo ...............................................................................................  17 
2.2.1.  Vitiligo, endogenous opioids and CRH-POMC system ..........  19 
2.2.2.  Vitiligo and genes connected to IL10 family cytokines ..........  22 
2.2.3.  Vitiligo and Dopamine pathway ..............................................  24 
3.  AIMS OF THE STUDY ............................................................................  27 
4.  MATERIALS AND METHODS ..............................................................  28 
4.1. Ethical considerations ........................................................................  28 
4.2. Characteristics of study participants ...................................................  28 
4.3. Analysis of mRNA expression ...........................................................  31 
4.3.1.  Sample collection and RNA extraction  from skin  
biopsies and PBMCs ...............................................................  31 
4.3.2.  cDNA synthesis .......................................................................  31 
4.3.3.  Quantitative real-time polymerase chain  reaction analysis ....  32 
4.3.4.  mRNA expression data analysis ..............................................  33 
4.4.  Protein level measurements ...............................................................  33 
4.4.1. Tissue homogenization for protein measurements ..................  33 
4.4.2. ELISA ......................................................................................  33 
4.4.3. Protein expression data analysis ..............................................  33 
5.  RESULTS .................................................................................................  34 
5.1.  Analysis of the expression profile of CRH-POMC system  
genes in vitiligo skin biopsies ...........................................................  34 
5.1.1. mRNA expression in skin biopsies .........................................  34 
5.2.  The mRNA expression profile of cytokines related to the  
regulation of melanocyte functioning  in vitiligo skin  
biopsy samples and peripheral blood mononuclear cells ..................  35 
5.2.1.  mRNA expression in skin biopsies and PBMCs .....................  35 
5.3.  The expression profile of genes associated  with the dopamine  
pathway in vitiligo skin  biopsies and blood sera .............................  39 
5.3.1. mRNA expression in skin biopsies .........................................  39 
5.3.2. Protein expression level in skin biopsies .................................  41 
5.3.3. Protein expression level in blood sera .....................................  41 
 
 2
6 
6.  DISCUSSION............................................................................................  43 
6.1.  Analysis of the expression profile of CRH-POMC system  
genes in vitiligo skin biopsies ...........................................................  43 
6.2.  The mRNA expression profile of cytokines associated with  
the regulation of melanocyte functioning in vitiligo skin  
biopsy samples and peripheral blood mononuclear cells ..................  45 
6.3.  The expression profile of genes associated  with the dopamine  
pathway in vitiligo skin  biopsies and blood sera .............................  49 
6.4.  Local HPA axis in vitiligo skin ........................................................  52 
7.  CONCLUSION .........................................................................................  56 
8.  FUTURE PROSPECTS .............................................................................  58 
9.  REFERENCES ..........................................................................................  59 
10. SUMMARY IN ESTONIAN ...................................................................  77 
11. AKNOWLEDGEMENTS ........................................................................  82 
PUBLICATIONS ...........................................................................................  85 
CURRICULUM VITAE ................................................................................  111 
 
 
7 
LIST OF ORIGINAL PUBLICATIONS 
I Reimann, E., Kingo, K., Karelson, M., Salum, T., Aunin, E., Reemann, P., 
Abram, K., Vasar, E., Silm, H., Kõks, S. Analysis of the expression profile 
of CRH-POMC system genes in vitiligo skin biopsies. Journal of Derma-
tological Science. 2010 Nov; 60(2): 125–8. 
II Reimann, E., Kingo, K., Karelson, M., Reemann, P., Loite, U., Sulakatko, 
H., Keermann, M, Raud, K., Abram, K., Vasar, E., Silm, H., Kõks, S. The 
mRNA expression profile of cytokines connected to the regulation of 
melanocyte functioning in vitiligo skin biopsy samples and peripheral 
blood mononuclear cells. Human Immunolog. 2012 Apr; 73(4): 393–8. 
III Reimann, E., Kingo, K., Karelson, M., Reemann, P., Loite, U., Keermann, 
M., Abram. K., Vasar, E., Silm, H., Kõks, S. The expression profile of 
genes associated to dopamine pathway in vitiligo skin biopsies and blood 
sera. Dermatology. 2012 May; 224(2): 168–76. 
 
 
Author’s contribution:  
I Study design, RNA extraction from skin biopsies, cDNA synthesis and 
detection using TaqMan QRT-PCR method, statistical analysis. The author 
wrote the manuscript and handled the correspondence.  
II Study design, extracting peripheral blood mononuclear cells (PBMCs) from 
total blood, RNA extraction from skin biopsies and PBMCs, cDNA syn-
thesis and detection using TaqMan QRT-PCR method, statistical analysis. 
The author wrote the manuscript and handled the correspondence. 
III Study design, extracting blood sera from total blood, RNA extraction from 
skin biopsies, cDNA synthesis and detection using TaqMan QRT-PCR 
method, homogenizing skin biopsies for protein measuring, protein expres-
sion measuring applying ELISA, statistical analysis. The author wrote the 
manuscript and handled the correspondence.  
 
8 
ABBREVIATIONS 
4a-OH-BH4 4a-hydroxy- tetrahydrobiopterin 
6BH4 6(R)-L-erythro 5,6,7,8 tetrahydrobiopterin 
ACTH adrenocorticotropin 
AGRP agouti-related protein 
APC antigen presenting cell 
ASIP agouti signalling protein 
ATRN attractin 
bFGF basic fibroblast growth factor 
cAMP cyclic adenosine monophosphate 
CAT catalase 
CD4+, 8+ cluster of differentiation 4+, 8+ 
CGRP calcitonin gene-related peptide 
CNS central nervous system 
CNTF ciliary neurotrophic factor 
COMT catechol-O-methyltransferase 
CRH corticotropin-releasing hormone 
CRHR1 corticotropin-releasing hormone receptor type 1 
DA dopamine 
DBH dopamine beta-hydroxylase 
DDC dopa decarboxylase 
DRD1-5 dopamine receptor 1-5 
E epinephrine 
GM-CSF granulocyte macrophage colony-stimulating factor 
Gp130 glycoprotein 130 
GPX1 glutation peroxidase 
GR glucocorticoid receptor 
GWAS genome wide association study 
HPA axis hypothalamic-pituitary-adrenal axis 
HPRT1 hypoxanthine phosphoribosyl-transferase 1 
ICAM1 intercellular adhesion molecule 1 
IFN interferon 
INFA interferon alpha 
INFB interferon beta 
INFG interferon gamma 
IL28A (IFNL2) interleukin 28 alpha (interferon lambda 2) 
IL28B (IFNL3)  interleukin 28 beta (interferon lambda 3) 
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1. INTRODUCTION 
The skin, the largest organ in the body, plays a critical role in maintaining inter-
nal homeostasis, serving as a barrier between the external environment and the 
internal milieu. [1] Because of its location, the skin is exposed continuously to a 
fluctuating environment with potentially noxious stimuli. [1, 2] It thus requires 
a precise and focused mechanism for the immediacy of its interactions with 
environmental stressors; preferably, such a mechanism should already be acti-
vated while cellular/tissue damage is still contained and of low magnitude. Such 
mechanisms are formed by the epidermal barrier, the secretory activity of 
adnexal structures, the local pigmentary and immune systems, vascular and 
mesenchymal components of the dermis. [1, 3–8] During the last few years, a 
modern concept of an interactive network between cutaneous nerves, the neuro-
endocrine axis, and the immune system has been established. This response 
system would restrict tissue damage and restore local homeostasis. [1] 
One of the most important systems for maintaining the basal and stress-
related homeostasis is the classical hypothalamic-pituitary-adrenal (HPA) axis. 
The required elements for the pathway are produced in hypothalamus, anterior 
lobe of the pituitary gland, and adrenal cortex. [9] The skin is also able to 
express all the elements of the HPA axis including the corticotropin-releasing 
hormone (CRH), proopiomelanocortin (POMC), adrenocorticotropin (ACTH) 
and β-endorphin with corresponding receptors, the glucocorticoidogenic 
pathway (primarily cortisol, a potent anti-inflammatory agent), and the gluco-
corticoid receptor (GR). Thus, there is a cutaneous HPA axis, which affects the 
immune system locally, but most probably influences the whole organism sys-
temically. [9–13] Similarly to the classical HPA axis, the functioning of the 
local HPA axis is also regulated by different mediators, i.e. cytokines and neu-
rotransmitters. [13–22] 
Vitiligo is an idiopathic disorder, where selective destruction of the skin 
melanocytes results in the development of depigmented patches. It affects 0.5–
2% of the general population without any racial, sexual, or regional differences 
in prevalence. [23, 24] In addition, patients often have other autoimmune 
diseases; furthermore, they suffer from psychological stress and the depig-
mented patches are more susceptible to sunburns, and thus skin cancer may 
develop. [23–28] Until now, the cause of vitiligo has not been fully understood; 
thus, different factors potentially participate and there are several theories – 
autoimmune, neural, and biochemical hypotheses. [29–34] 
In the case of vitiligo pathogenesis, the pathways, which participate or 
potentially affect the cutaneous HPA axis, have been demonstrated to be altered 
to some extent. Our group has previously demonstrated significant differences 
in POMC system peptides and receptors in vitiligo patients compared to 
controls. [35] The expression of POMC, the key pro-peptide for HPA axis, 
decreased in patients’ involved skin and also the melanocortin receptor level 
decreased in lesions. [9, 35] 
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Additionally, the expression of cytokines and the amount of neuromediators, 
which regulate the activity of HPA axis, i.e. interleukin-1 (IL1), IL6, and 
tumour necrosis factor alpha (TNFA), dopamine, norepinephrine, has altered in 
the blood and skin of vitiligo patients. [14, 22, 34, 36–40] Our group has pre-
viously studied the IL10 cytokine family and their receptors in vitiligo patients. 
We were not able to see any significant decrease in anti-inflammatory IL10 
expression as shown by previous studies. [37, 41] Thus, we found that the pro-
inflammatory IL22 expression had increased in the blood of vitiligo patients; 
also the expression of pro-apoptotic IL24 and receptor subunits IL10 receptor A 
and B (IL10RA and IL10RB) had increased in patients’ blood. [37] In addition, 
we found associations between the polymorphisms of IL19 and vitiligo patho-
genesis. [42] 
The aim of this research was to obtain further information about the different 
participating pathways in the functioning and possibly regulating the cutaneous 
HPA axis; the author intended to demonstrate the expression pattern changes of 
the studied genes in the case of vitiligo pathogenesis. The endogenous opioids 
pathway was analysed together with CRH and melanin-concentrating hormone 
(MCH) pathways, IL10 cytokine family and associated pathways and the 
dopamine pathway.  
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2. REVIEW OF LITERATURE 
2.1. Skin as a neuroimmunoendocrine organ 
The strategic location of the skin as the barrier between the environment and the 
internal milieu determines its critical function in the preservation of body 
homeostasis. [1] The skin is continuously exposed to many hostile environ-
mental factors and to acute transfers of solar, thermal, or mechanical energy. [2] 
There are several instant mechanisms for the restoration of the structural and 
functional integrity of the skin upon disruption. Such mechanisms include the 
barrier-forming properties of the epidermis, the secretory activity of adnexal 
structures, the immune and pigmentary systems of the skin, as well as vascular 
and mesenchymal components of the dermis. [3, 5–8] 
Skin is composed of three primary layers: the epidermis, the dermis, and the 
hypodermis. In addition to the barrier and defensive functions, skin as the 
largest organ in humans has several other important purposes among which the 
sensation of heat and cold, touch, pressure, vibration and tissue injury are 
mostly connected to the central nervous system (CNS) directly via efferent 
nerves or CNS derived mediators or indirectly via the adrenal glands or immune 
cells. Both sensory and autonomic (sympathetic) nerves influence a variety of 
physiological (vasocontraction, vasodilation, body temperature, barrier func-
tion, secretion, cell growth, differentiation, nutrition) and pathophysiological 
(inflammation, immune defence, apoptosis, proliferation, wound healing) func-
tions in the skin. [43, 44] 
In the skin, cutaneous nerve fibres are principally sensory with additional 
complement autonomic nerve fibres. [45] Most nerve fibres are found in the 
mid-dermis and the papillary dermis, but also in the epidermis, blood vessels, 
hair follicles, sebaceous glands, sweat glands, and apocrine glands forming a 
three-dimensional network. [46, 47] In contrast to sensory nerves, autonomic 
nerves never innervate the epidermis in mammals. [45] Autonomic nerve fibres 
in the skin almost completely derive from sympathetic (cholinergic) and, in the 
face, rarely from parasympathetic (also cholinergic) neurons. [48] Although 
very effective, they constitute only a minority of cutaneous nerve fibres com-
pared with sensory nerves. Autonomic nerves innervate blood vessels, an-
terovenous anastomoses, lymphatic vessels, erector pili muscles, eccrine glands, 
apocrine glands and hair follicles. [49] Both autonomic as well as sensory nerve 
fibres are involved in hair follicle cycling and inflammation. [50] 
As is common to neurons, cutaneous cells, such as keratinocytes, melano-
cytes, microvascular endothelial cells, Merkel cells, fibroblasts, leukocytes are 
also capable of releasing neuropeptides. All epidermal cells express sensor 
proteins and neuropeptides regulating the neuro immuno-cutaneous system. The 
epidermis can be considered a true sensory tissue where sensor proteins and 
neuron-like properties enable epidermal cells to participate in the skin surface 
perception through interactions with nerve fibres. [51, 52] Dermal blood vessels 
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are highly innervated by sensory and autonomic nerve fibres, they also syn-
thesize certain neuropeptides after activation and express receptors for neu-
ropeptides, which suggests that a complex autocrine and paracrine neuro-
endocrine system may exist in the skin. [53] 
Langerhans cells and mast cells are key cells between neuroendocrine and 
immune systems in skin. They participate in the endocrine system through the 
metabolism of vitamin D and production of neurohormones. [54, 55] Langer-
hans cells are closely connected to Merkel cells and with sensory neurons, the 
latter interaction inhibits the antigen presenting function of Langerhans cells, 
acting as an immunomodulator. [56] [57, 58] Merkel cells are tightly interacted 
with neurons and are the only excitable cells within the epidermis, in addition to 
neurons; however, the activating stimuli are still not clear. [59–61] Langerhans 
and Merkel cells produce different mediators, which influence keratinocytes 
and melanocytes, i.e. IL10 family cytokines IL19, IL20, IL24, IL28 and IL29. 
[62, 63] 
Keratinocytes modulate the innate and adaptive immune responses; they 
produce antimicrobial peptides and chemokines (independently from epidermal 
or dermal immune cells) and are able to activate T cells directly, but also indi-
rectly via antigen presenting cells (APCs; dendritic cells and Langerhans cells) 
in the skin. [64–69] For that purpose, keratinocytes express different cytokines 
e.g. IL1, IL8, IL25, TNFA. [68, 70–73] They also produce mitogens, such as 
basic fibroblast growth factor (bFGF), endothelins, stem cell factor (SCF), 
hepatocyte growth factor, nerve growth factor, granulocyte macrophage colony-
stimulating factor (GM-CSF), leukemia inhibitory factor (LIF), -melano-
genesis stimulating hormone (MSH), ACTH, which are essential for regu-
lating differentiation, growth, and survival of melanocytes. [74–76] Addi-
tionally, they produce IL10 family cytokines i.e. IL10, IL19, IL20, IL24. [77–
79] 
Melanocytes synthesize melanin pigments when the skin is exposed to the 
sun. Ultraviolet (UV) radiation-stimulated melanocytes produce POMC. [80] 
POMC derived -, -, -MSH, ACTH, -, -lipotropin (LPH), and -endorphin 
[81] can activate melanogenesis, stimulate epidermal cell proliferation, induce 
melanocytes and Merkel cells to rise to a suprabasal location, have immuno-
suppressive and anti-inflammatory effects, probably through calcitonin gene-
related peptide (CGRP) and IL10, or can even elevate the intensity of the cuta-
neous innervations. [82, 83] Furthermore, in skin the melanocytes are the prin-
cipal source of anti-inflammatory IL10. [84]  
 
 
2.1.1. Neuroendocrine axes: cutaneous HPA axis 
In addition to endocrine activities, where hormones, neurotransmitters, neu-
ropeptides, and the corresponding receptors are produced by epidermal, 
adnexal, and dermal cells or released in situ from cutaneous nerve endings, 
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adnexal structures, e.g. eccrine, apocrine and sebaceous glands and hair follicles 
also perform cutaneous exocrine activities. [1, 6, 8] The function of the latter is 
to strengthen the epidermal barrier, to regulate thermoregulation, or to par-
ticipate in the defence against microorganisms or in social communication. [1, 
5–8] All these activities can be organized into cutaneous neuroendocrine axes. 
[85] Special attention should be paid to a cutaneous equivalent of the HPA axis 
that would regulate local responses to stress independently from the central 
level. [86] Among others are local cholinergic, catecholaminergic, and sero-
toninergic/melatoninergic systems, the steroidonergic pathway in the skin and 
cutaneous expression of the pituitary-thyroid axis elements. [1, 87–95].  
The classical HPA axis mediates the main adaptive responses to systemic stress 
(Figure 1). [9] Activation of the HPA system starts with hypothalamic pro-
duction of CRH, which in the anterior activates CRH receptor type 1 (CRHR1) 
and induces production and release of POMC-derived peptides ACTH, MSH 
and -endorphin. [10–12] ACTH stimulates production and secretion of cortisol 
by the adrenal cortex. [9–12] 
 
 
 
Figure 1. Classical and cutaneous HPA axis. [96] 
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The HPA axis is regulated at several levels, including stimulatory or inhibitory 
signals from the brain mediated through neurotransmitter systems and the 
suppressive feedback influence of corticosteroids themselves. Cortisol affects 
the HPA axis through binding to the GR located in hypothalamus and pituitary. 
[14] In addition, the axis is regulated by the endogenous opioid system – the 
opioid receptor  (OPRM) activation by -endorphin inhibits both production 
of CRH in the hypothalamus and POMC peptides in the anterior pituitary. [97, 
98] Other neuromediators also participate in regulating the HPA axis activity. In 
the case of dopamine it has been found that during stress it has an adaptive, 
negative feedback capacity preventing excessive HPA axis activation in the rat 
brain. [14] The norepinephrine system as a quick stress response pathway has 
synergistic effects with a slower responding HPA axis. [15] Norepinephrine can 
excite CRH production and activate the HPA axis. [16] Serotonin activates the 
HPA axis in mice by increasing the expression of CRH. [17] 
The neuroendocrine and immune systems communicate bidirectionally. The 
neuro-immune-endocrine interface is mediated by cytokines acting as 
auto/paracrine or endocrine factors regulating pituitary development, cell pro-
liferation, hormone secretion, and feedback control of the HPA axis. [18] Com-
plex interactions have been described for cytokine actions, including over-
lapping, synergistic, and antagonistic activities. By stimulating the HPA axis 
cytokines antagonize their own peripheral pro-inflammatory action. Excess 
HPA axis stimulation leads to immunosuppression and, therefore, increased 
susceptibility to infection. [13, 18] The concept of distinct groups of pro-in-
flammatory and anti-inflammatory cytokines has emerged on the basis of their 
peripheral action. [19] Glycoprotein 130 (Gp130), cytokine family (LIF, IL6, 
IL11, ciliary neurotrophic factor (CNTF), and oncostatin M (OSM)) participate 
in ACTH regulation and mediates the immuno-neuroendocrine interface. [20, 
21] The most thoroughly studied cytokines are IL1, IL6, and TNFA, which 
activate the HPA axis in response to various threats to homeostasis. [22] 
Skin cells are able to produce CRH and related peptides urocortin (URC) 1 
and 2. In humans, the CRH and its receptor CRHR1 expression are stimulated 
by UV radiation. [2, 5, 86, 99, 100] CRHR1, which is activated by both CRH 
and URC, is predominantly expressed in the epidermis; the signal transduction 
pathways are coupled to cAMP, IP3, and Ca2+. [96, 101–103] POMC and recep-
tors for its derivates are also produced and processed in skin. The process is 
upregulated by UV radiation and increasing cAMP levels. Activation of the 
melanocortin receptors regulates or modifies several skin functions including 
pigmentation and local and possibly systemic immune activity. [2, 4, 104, 105] 
Cortisol and corticosterone are synthesized in hair follicles and melanocytes and 
fibroblasts. [101, 106, 107] Thus, Slominski et al. have proposed that the cuta-
neous defence against stressors is organized as an equivalent of HPA axis that 
operates as a coordinator and executor of the local responses to stress 
(Figure 1). [108] 
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In skin the cascade possibly goes as follows: CRH activates CRHR1 and 
further POMC expression and ACTH production in fibroblasts and melanocytes 
but not in epidermal keratinocytes. [107] In response to CRH and ACTH, 
melanocytes produce higher levels of cortisol and corticosterone, while fibro-
blasts only enhance the production of corticosterone, but not cortisol, which is 
produced continuously. [107] In the case of hair follicle keratinocytes, the 
CRH-POMC-cortisol cascade has been demonstrated to be functionional. [109]  
As with the classical HPA axis, cytokines also control the activity of the 
cutaneous HPA axis. The cytokine IL1 has significant stimulatory effects on 
POMC gene expression and on the production of POMC-derived ACTH, 
MSH, and LPH peptides by resident skin cells and circulating immune cells. 
[110–113] IL1 also stimulates melanocortin 1 receptor (MC1R) expression. 
[114–117] TNFA stimulates POMC gene expression in dermal fibroblasts; 
transforming growth factor beta (TGFB) has the opposite effect, inhibiting 
POMC gene expression in the same cell system and in keratinocytes. [118] 
Endothelin-1, interferon alpha, beta and gamma (INFA, INFB, and INFG) can 
also stimulate the expression of functional MSH receptors on melanocytes. 
[105, 114, 115, 119–121] Thus, the cutaneous immune system also participates, 
through the opposing action of selected cytokines, in the regulation of the local 
HPA axis.  
 
 
2.2. Vitiligo  
Vitiligo is characterized by progressive disappearance of skin pigment cells, 
with straightforward clinical translation – white macules or white hair appear, 
usually without any accompanying clinical symptoms. Vitiligo occurs world-
wide with an estimate prevalence of 0.5–2% in most populations. In almost half 
of the patients vitiligo starts before the age of 20 years, and males and females 
are affected with approximately equal frequency. [23, 24] Vitiligo has been 
associated with concomitant occurrence with a number of other autoimmune 
diseases, as well as a wide range of psychosocial difficulties, significantly, 
impacting quality of life. [25–27] 
In the involved vitiligo, skin melanocytes are partially or completely lost, 
and no melanin is synthesized in this area. The cause of destruction of epi-
dermal or follicular melanocytes is complex and not yet fully understood; how-
ever, there are several theories (autoimmune, neural, and biochemical hypothe-
ses). [29, 30] Melanocyte death may occur due to the factors from inside and/or 
outside the cell and many potential systems could be involved. Histological data 
have demonstrated that at the perilesional skin in patients with non-segmental 
vitiligo an inflammatory infiltrate of low intensity made of mononuclear cells 
occurs in the upper dermis and the dermal-epidermal interface. [122] The initia-
tion mechanism of this microinflammatory reaction is still unknown, but it has 
been suggested that various local triggers alert the skin innate immune system 
5  
18 
and may precede adaptive immune responses targeting melanocytes. [123, 124] 
The absence of melanocytes affects skin homeostasis, as noted for skin sensiti-
zation, skin dermal neural responses, photoadaption, and redox status. [122]  
The genome wide association studies (GWAS) account for a limited part of 
the heritability of the disease but may mediate a crucial part of disease pheno-
type, such as progression or age at onset. [125] Most vitiligo susceptibility loci 
encode immunoregulatory proteins or melanocyte components that are likely to 
mediate immune targeting and the relationships among vitiligo, melanoma, and 
eye, skin, and hair coloration. [126] For example, associations have been estab-
lished between vitiligo pathogenesis and polymorphisms in tyrosinase gene 
(TYR), catalase gene (CAT), MC1R, major histocompatibility complex genes 
(MHC), protein tyrosine phosphatase non-receptor type 22 gene (PTPN22), 
NLR family pyrin domain containing 1 gene (NLRP1), and X box binding pro-
tein 1 gene (XBP1). Both protective and susceptibility increasing effects have 
been found in the case of different polymorphisms in these genes. [127, 128] 
Additionally, Koebner’s phenomenon is considered, according to which the 
induction of an isomorphic lesion follows a trauma. However, the significance 
of the phenomenon is controversial: does it indicate an intrinsically poor 
melanocyte attachment (melanocytorrhagy theory), or is it related to local 
inflammatory activity and overall disease progression. [129, 130]  
Vitiligo has been classified on the basis of clinical grounds into two major 
forms: segmental (SV) and non-segmental vitiligo (NSV), the latter including 
generalized, acrofacial, and universal vitiligo. [131] The term vulgaris (synony-
mous with “common”, a subgroup of generalized vitiligo) should not be used 
according to the Vitiligo Global Issues Consensus Conference (VGICC; held in 
2011) (Table 1). However, while the samples for our studies had been collected 
prior to this decision, the term is still valid in the present dissertation. [132] 
NSV is characterized by depigmented macules that vary in size from a few to 
several centimetres in diameter, often involving both sides of the body with a 
tendency towards symmetrical distribution. SV has a limited, segmental distri-
bution, has an earlier onset than NSV; its course is rapidly progressive but lim-
ited – depigmentation spreads within the segment over a period of 6–24 months 
and then stops. In contrast to NSV, SV has early involvement of melanocytes of 
hair follicles. [133] Mixed vitiligo is coexistence of SV and NSV. Focal vitiligo 
refers to an acquired, small, isolated hypopigmented lesion that does not fit a 
typical segmental distribution and which has not evolved into NSV after a 
period of 1–2 years. [132] Mucosal vitiligo involves oral and/or genital muco-
sae. [132] Universal vitiligo corresponds to complete or nearly complete depig-
mentation of the skin. [32, 132] The neural hypothesis is thought to be involved 
in SV whereas the autoimmune hypothesis is commonly related to NSV or focal 
vitiligo. [30] Regardless of this complicated classification, different studies 
suggest rather a continuum bridging all forms of vitiligo around a transient 
auto-inflammatory phase, which is associated with the wiping out of melano-
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cytes, and a predisposing background to develop autoimmune responses that 
follow a risk gradient from SV to NSV. [122, 129, 130, 134, 135] 
 
Table 1. Vitiligo classification according to the Vitiligo Global Issues Consensus Con-
ference (held in 2011) [132] 
 Subtypes 
Non-segmental vitiligo Acrofacial 
Mucosal (more than one mucosal sites) 
Generalized 
Universal 
Mixed 
Rare variants 
Segmental vitiligo Uni-, bi-, or plurisegmental 
Undetermined/unclassified vitiligo Focal 
Mucosal (one site in isolation) 
 
 
2.2.1. Vitiligo, endogenous opioids and CRH-POMC system 
Neuropeptides, including endogenous opioids and hormones, are mainly pro-
duced by neurons to communicate with each other. They may also be synthe-
sized locally in skin involving the perception of pain and itch sensation and 
regulating melanogenesis and melanin transport to surrounding keratinocytes. 
[136, 137] We have previously studied the melanocortin system, which is an 
essential coordinator and executor of responses to stress. It consists of POMC, 
agouti signalling protein (ASIP), agouti related protein (AGRP) and the family 
of five melanocortin receptor genes (MC1-5R). The melanocortin system is 
important part of the CRH-POMC system, which is highly organized in skin-
generating functions analogous to the HPA axis. [104, 138] We showed that the 
POMC mRNA expression level is significantly lower in the involved skin of 
vitiligo patients compared to uninvolved skin. The mRNA expression level of 
MC1R and MC4R decreased in involved skin comparing to uninvolved skin; 
however, the expression is evidently higher in uninvolved skin than in the skin 
of controls. [138] 
The system of endogenous opioids includes several groups of different neu-
romediators – endorphins, enkephalins, dynorphins, endomorphins, nociceptins, 
and their receptors. Endogenous opioids are synthesized from different pre-
cursors; in addition to the POMC gene, there are prodynorphin (PDYN), pre-
pronociceptin (PNOC), and proenkephalin (PENK) genes (Figure 2). PDYN 
codes leu-enkephalin, dynorhin A and B, α- and β- neodynorphin and ‘big 
dynorphin’ (consists dynorphin A and B), which bind to different receptors – 
mu 1, delta 1, kappa 1 opioid receptors (OPRM1, OPRD1, OPRK1 genes, re-
spectively). PNOC codes Noc II, nociceptin and nocistatin, all three bind to 
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opioid receptor like 1 (OPRL1). PENK codes both met-and leu-enkephalin 
petides, which bind to OPRM1, OPRD1, and OPRK1. [139] 
Not much is known about the functions of products of PDYN and PNOC 
genes, which may involve the skin. Nociceptin is believed to play a role in no-
ciceptive functions and increased adaptation to stress. [140, 141] Dynorphin A 
is known to participate in nociception and hyperalgesia and in inducing migra-
tion of keratinocytes and wound healing. [142–144] It has been suggested that 
OPRM1 and OPRD1 may have a role in keratinocyte proliferation and dif-
ferentiation. [145] Β-endorphin may stimulate melanocyte proliferation through 
OPRM1. [146, 147] Opioids may affect the skin also through immune cells. For 
example, OPRD1 is upregulated in T cells during activation in vitro and in vivo. 
[148] Endogenous opioids reduce leukocyte proliferation through OPRM1, 
which has a positive correlation with human melanoma progression. [149] In 
psoriatic skin the level of dynorphin A and OPRK1 has decreased compared to 
healthy skin. [150] OPRM1 is down-regulated by β- endorphin and its expres-
sion has decreased in psoriatic skin. [151] No associations with vitiligo patho-
genesis have been demonstrated. 
 
 
 
Figure 2. Components connected to the CRH-POMC system: POMC, proopiome-
lanocortin; PENK, proenkephalin; PDYN, prodynorphin; PNOC, prepronociceptin, 
CRH, corticotropin-releasing hormone; PMCH, pro-melanin-concentrating hormone; 
ASIP, agouti signalling protein; OPRM1 and -2, opioid receptor mu 1 and 2; OPRD1, 
opioid receptor delta 1; OPRK1 and -2, opioid receptor kappa 1 and 2; OPRL1, opioid 
receptor like 1; NMDA-glutamate receptor, N-methyl-D-aspartic acid-glutamate recep-
tor; CRHR1 and 2, corticotropin-releasing hormone receptor 1 and 2; MCHR1 and 2, 
melanin-concentrating hormone receptor 1 and 2; ATRN, attractin; NURR1, nuclear 
receptor related 1 
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Until December 2010, there was no data about PENK mRNA expression in the 
skin; however, antibodies against met-enkephalin have been found. [152] 
Slominski et al. demonstrated PENK expression in fibroblasts, keratinocytes, 
and melanoma cells. [153] Depending on the site of production or target cells, 
the PENK-derived peptides can act in a para- or autocrine manner affecting 
immune activities, having direct antimicrobial activities, regulating cell pro-
liferation and differentiation. [154–159] It was discovered in vitiligo patients 
that the met-enkephalin level in the patients’ blood sera had increased and the 
daily circadian rhythm had changed. [160] There is no data available about any 
associations between leu-enkephalin with vitiligo pathogenesis. 
CRH and its receptor CRHR1 are the central components of the HPA axis 
and important in coordinating systemic stress. [161] While CRH and CRHR1 
are expressed also in human skin, they are believed to regulate various func-
tions there. In the skin the CRH system is closely connected to the POMC sys-
tem; CRH enhances the production and secretion of POMC and its peptides 
(MSH, ACTH, endorphin). POMC, however, is an important regulator of 
melanogenesis and survival of the melanocytes. This CRH-POMC skin system 
seems to have a major role in maintaining skin integrity and homeostasis. [162–
166]  
In mammals, the melanin-concentrating hormone (MCH) serves mainly as a 
neuropeptide, which is found in many regions of the brain [167]. Using dif-
ferent methods melanin-concentrating hormone receptor 1 (MCHR1) expres-
sion has been detected in melanocytes but not in keratinocytes or fibroblasts. 
[168] No MCHR2 expression has been demonstrated in any skin cells. [169, 
170] In the skin, the MCH system is connected to the POMC system; MCH is 
known to inhibit the αMSH induced cAMP accumulation in cultured human 
melanocytes, resulting in reduced melanin production. This finding suggests 
that MCH may oppose the actions of the melanocortin system. [168, 171] Asso-
ciations between the MCH-MCHR1 system and vitiligo pathogenesis have been 
investigated – autoantibodies against MCHR1 have been found in the patients’ 
blood sera; however, the amount of antibodies is not correlated to the activity of 
the disease. [172, 173] 
Also connected to the POMC system, attractin (ATRN) is a receptor for 
melanogenesis inhibiting agouti protein in mice. [174] ATRN is rapidly upregu-
lated on the membrane of activated T cells and the soluble form is also released 
from there. It is known that loss of ATRN results in repercussion of skin pig-
mentation in mice. [175] The nuclear receptor related 1 protein (NURR1) 
induces and functions downstream MC1R signalling in melanocytes. [176] 
NURR1 is thought to mediate the effects of CRH and is involved in at least two 
signalling pathways mediating inflammatory signals. [177, 178] It has a key 
role in maintaining the dopaminergic system of the brain. [179] 
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2.2.2. Vitiligo and genes connected to IL10 family cytokines 
The autoimmune theory of the destruction of melanocytes has a wide range of 
supportive evidence – abnormalities in both humoral and cell-mediated 
immunity have been documented in vitiligo patients. [30, 180] Additionally, 
vitiligo is associated with an increased local and systemic cytokine production. 
[181–186] 
The IL10 cytokine family contains interleukins with a limited primary 
sequence similarity and structural homology and common receptor subunits, but 
distinct physiological roles. [187–189] In addition to IL10, the superfamily 
consists of IL19, IL20, IL22, IL24, and IL26. [187] IL28A (interferon lambda 2 
(IFNL2)), IL28B (IFNL3) and IL29 (IFNL1) are recent members of the IL10 
cytokine family (also categorized under the interferon family). [190] 
IL10 is most abundantly produced by monocytes and type 2 T helper cells; 
however, also by mast cells, keratinocytes, dendritic cells, and eosinophiles. 
[191–193] It is an important immunomodulatoy cytokine, which has an anti-
inflammatory effect while inhibiting the synthesis of pro-inflammatory cyto-
kines produced by type 1 T helper cells. Thus, it may also stimulate certain T 
cells, mast cells as well as antibody production and maturation of B cells. [41, 
194, 195] IL10 is associated with many autoimmune and inflammatory 
diseases, such as rheumatoid arthritis, psoriasis, melanoma and systemic lupus 
erythematosus. [196–200] IL19 is produced by monocytes, B cells, and 
keratinocytes, and it has been reported to have a direct effect on immune cells. 
[187, 201, 202] It is associated with psoriasis and asthma. [203, 204] IL20 is 
synthesized in monocytes and keratinocytes, and its over-expression provokes 
psoriasis-like skin lesions, which suggests its involvement in inflammatory 
response in the skin. [205, 206] IL22, which is produced by natural killer cells, 
T helper cells, fibroblasts, macrophages, mast cells, and dendritic cells, induces 
the expression of different pro-inflammatory molecules. [202, 205, 207–209] 
While mostly derived from T cells, IL22 may have a role in innate immunity of 
the skin and is associated with rheumatoid arthritis and psoriasis. [37, 207, 208, 
210] IL24 is mainly synthesized by monocytes, macrophages, and type 2 T 
helper cells; it is known as pro-apoptotic cytokine and is cytotoxic for various 
tumour cells, including melanoma. [202, 205, 211–213] IL26 is mainly pro-
duced by T cells, monocytes, and natural killer cells [202], and it is involved in 
the activation of signal-transducer and activator of transcription protein 1 and 3 
(STAT1 and STAT3) pathways, which are important for the stimulation of 
IL10, IL8, and intercellular adhesion molecule 1 (ICAM1) production. [214] 
IL28A, IL28B and IL29 are produced by T cells, dendritic cells, and virus-
infected cells; they are believed to have antiviral, antiproliferative, and anti-
tumor activity. [190] In addition, lipopolysaccharide (LPS) stimulation appears 
to induce the secretion of IL10 family cytokines suggesting their involvement in 
the innate immune response. [205, 215] 
Our previous study failed to detect IL10 mRNA expression in the skin, and 
PBMCs did not reveal any significant differences between vitiligo patients and 
23 
controls. The protein level has a tendency to decrease in sera (statistically in-
significant). [37] Thus, according to other studies, the IL10 protein level in 
vitiligo skin has decreased. [41] In the PBMCs of vitiligo patients the expres-
sion of IL19 has elevated, and there are associations between the poly-
morphisms of IL19 and vitiligo pathogenesis. [37, 42] LPS increases the IL20 
mRNA level in the PBMCs of controls but not in vitiligo patients. [37] The 
mRNA and protein expression of IL22 is elevated in patients’ PBMCs and sera, 
respectively. [37, 207] Similarly to IL20, LPS stimulation affects the IL24 mRNA 
expression only in the PBMCs of controls but not in vitiligo patients. [37]  
The receptor subunits for IL10 family cytokines form different receptor 
complexes, on which the ligands can bind (Figure 3). IL10RB is expressed in 
most cells; thus, IL10RA primarily in lymphocytes, monocytes, natural killer 
cells, and dendritic cells. [202] IL20RA, IL20RB, and IL22RA1 levels are the 
highest in epithelial and stromal cells. They are expressed together in con-
siderable levels only in skin and lung tissue. [202, 205] IL22RA2 is mostly 
produced by plasma cells, monocytes, B and T cells, and dendritic cells. [202, 
216] IL28RA is expressed in monocytes and dendritic cells, thus, most probably 
also in keratinocytes and melanocytes. [62, 63] 
The expression of the receptors of IL10 family cytokines has altered in dif-
ferent pathogeneses, such as psoriasis, melanoma, and chronic atopic eczema; 
also UV radiation affects the expression pattern. [217–222] Our previous 
studies showed that the mRNA expression level of IL10RB and IL22RA1 had 
not altered in vitiligo skin. IL10RA has a tendency towards increased expres-
sion in vitiligo skin. mRNA expression of IL20RA decreased in patients’ skin. 
The mRNA expression of both IL10RA and IL10RB increased in patients’ 
PBMCs, the IL20RA and IL22RA1 mRNA levels were under detection limits. 
[37] Until now there is no data about IL22RA2 (inhibits IL22 activity [202, 
216]) and IL28RA (the receptor complex combining IL28RA and IL10RB for-
wards the signals of IL28A, IL28B, and IL29 [190]) associations with vitiligo 
pathogenesis.  
 
 
 
Figure 3. The receptor complexes for the IL10 family cytokines. [62, 63, 214, 223] 
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There are some genes that most probably are to some extent connected to IL10 
family cytokines. Nuclear protein homolog (mouse) gene (MDM1) is located 
together with IL22 and IL26 in the locus 12q15; however, the biological func-
tion of MDM1 is unknown. [224, 225] IFNA and IFNB bind to the same cell 
surface receptor (IFNAR). IFNA is produced by leukocytes and keratinocytes 
while IFNB is synthesized by a variety of cells (fibroblasts, epithelial cells, and 
macrophages). [226, 227] Both IFNA and IFNB mRNAs have been detected in 
normal human melanocytes. [228] IFNA might be important in enhancing bio-
logical defence activities against oxidative stress and may cause induction of 
anti-melanocyte autoantibodies or activation of cytotoxic T cells. [229–231] 
IFNB is thought to induce apoptosis and to have anti-proliferative effects on 
malignant cells. [232] IFNA, IFNB, and also IFNG enhance human B cell pro-
liferation. [233] Both IFNA and IFNB therapies may cause vitiligo. [230, 234, 
235] IFNG is predominantly produced by natural killer cells, cluster of differen-
tiation 4+ and 8+ (CD4+ and CD8+) T cells. [236] The association between IFNG 
and several skin conditions, such as atopic dermatitis, dermatomyositis, sys-
temic lupus erythematosus, psoriasis, and melanoma, has been demonstrated. 
[237–241] Its mRNA expression has increased in vitiligo-involved and un-
involved skin compared to control skin. [194, 242] IFNG stimulates the expres-
sion of ICAM1, which is important for activating T cells and recruiting leuko-
cytes. [243, 244] ICAM1 protein expression is upregulated in vitiligo skin and 
in melanocytes from perilesional vitiligo skin. [245] 
 
 
2.2.3. Vitiligo and Dopamine pathway 
There is considerable evidence that the melanocortin pathway, the most impor-
tant melanogenesis regulator, is functionally linked with the dopamine system. 
[5, 246] Dopaminergic compounds inhibit the secretion of MSH and -endor-
phin and affect POMC mRNA expression level in pituitary. [247, 248] Classi-
cally, catecholamines (dopamine, norepinephrine, and epinephrine) act as neu-
rotransmitters; however, they are also involved in regulative processes in the 
skin, which has a full capacity to synthesize these agents (Figure 4). [249, 250] 
Vesicular monoamine transporters 1 and 2 (VMAT1, VMAT2) participate in 
the removal of the dopamine from the cells. Also, several enzymes degrading 
catecholamines, such as monoamine oxidase A and B (MAOA, MAOB) and 
catechol-O-methyltransferase (COMT), are present in the epidermis. [251, 252] 
The dopamine pathway is potentially associated to melanoma – there are 
possible associations between L-DOPA and malignant melanoma; and psoriasis 
– immunoreactivity to PNMT increased ten times in lesional skin compared to 
unlesional skin; L-DOPA treatment relieves psoriasis in Parkinson’s disease 
patients. [253–256] Furthermore, until now the associations between vitiligo 
pathogenesis and genes connected to the dopamine pathway have been proven 
to some extent; however, the relations have not been fully understood as yet. 
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Both phenylalanine hydroxylase (PAH) and tyrosine hydroxylase (TH), which 
participate in catecholamine synthesis, use (6R)-L-erythro-5,6,7,8-tetrahydro-
biopterin (6BH4) as a cofactor. PAH and pterin-4a-carbinolamine dehydratase 
(PCD; essential for regenerating 6BH4 in the PAH system) activity has 
decreased in the skin and sera of vitiligo patients compared to controls, whereas 
the activity of TH has increased. [257, 258] Autoantibodies against TH have 
been found in patients, especially at an active stage of vitiligo. [259] Auto-
antibodies against dopa decarboxylase (DDC) have been found in the sera of 
80% of type I patients of the autoimmune polyendocrine syndrome, who also 
have vitiligo. [260] Also, the protein expression in patients’ epidermis is 
significantly lower in association with decreased serotonin and melatonin 
levels. [261] The activity of 6BH4 dependent enzyme phenylethanolamine  
N-methyltransferase (PNMT) has decreased in keratinocytes obtained from the 
involved skin of vitiligo patients and also when measured from whole skin 
samples. [251] 
 
 
Figure 4. Schematic representation of the catecholamine biosynthesis cascade, showing 
major intermediates and enzymes involved in the process. L-Phe – L-Phenylalanine,  
L-Tyr – L-Tyrosine, L-DOPA – L-3,4-dihydroxyphenylalanine, DA – dopamine, NE – 
norepinephrine, E – epinephrine, 6BH4 – 6(R)-L-erythro 5,6,7,8 tetrahydrobiopterin,  
4a-OH-BH4 – 4a-hydroxy- tetrahydrobiopterin, qBH2 – quinonoid dihydrobiopterin, 
PAH – Phe hydroxylase, TH – Tyr hydroxylase, DDC – dopa decarboxylase, DBH – 
dopamine beta-hydroxylase, PNMT – phenylethanolamine N-methyltransferase, PCD – 
pterin-4a-carbinolamine dehydratase. 
 
 
In vitiligo skin the elevated H2O2 level is the main cause of 6BH4 recycling 
errors. [262] The activity of enzymes important to metabolize H2O2 has 
impaired in patients’ skin and also systemically – the latter has been proven in 
the case of CAT and glutation peroxidase (GPX1). [263–265] The elevated 
6BH4 level stimulates the activity of TH, causing an increase of catecholamines 
in vitiligo skin and plasma. [39, 257] The higher level of catecholamines 
induces the activities of catecholamine degrading enzymes, which has been 
demonstrated in vitiligo skin in the case of MAOA and COMT. [251, 252] 
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Dopamine actions are mediated through five specific cell surface receptors 
coupled to G proteins and belonging to two main families (D1-like and D2-like 
receptors). [266] These receptors participate in the regulation of melanogenesis. 
The competitive interactions between MSH and the receptor agonist on dopa-
mine receptor D1 (DRD1) have been demonstrated. [267] DRD1B, DRD2, and 
DRD4 participate in the regulation of pigment synthesis and transport in photo-
receptor cells. [268, 269] DRD2 agonist has been shown to inhibit hair fol-
licular melanogenesis in mice, and DRD2 is present in a significant proportion 
of melanomas. [253, 270] 
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3. AIMS OF THE STUDY 
The main purpose of the studies presented here was to receive more information 
about the nervous and immune system interactions in the skin of vitiligo 
patients. The aim of these studies was to evaluate the possible role of different 
pathways in vitiligo pathogenesis: the endogenous opioids pathway together 
with the CRH and MCH pathway, IL10 cytokine family and associated path-
ways, the dopamine pathway. Most likely all these pathways participate in the 
function of the cutaneous HPA axis. For these purposes the following goals 
were set: 
 To evaluate the possible role of the CRH-POMC system and associated sys-
tems (MCH, endogenous opioids) in vitiligo pathogenesis by analysing the 
mRNA expression of the following genes in skin biopsies: CRH, CRHR1, 
PMCH, MCHR1, ATRN, NURR1, PDYN, PNOC, OPRD1, OPRK1, OPRM1, 
and OPRL1. 
 To analyse various cytokines, their receptors and some other genes po-
tentially related to the development, proliferation, and survival of melano-
cytes and the regulation of melanogenesis (IL20RB, IL22RA2, IL26, IL28A, 
IL28B, IL29, IL28RA, MDM1, IFNA1, IFNB1, IFNG and ICAM1) and to 
evaluate their possible role in vitiligo pathogenesis. For that purpose the 
mRNA levels in PBMCs and skin biopsies were observed. 
 To analyse the mRNA and protein expression of dopamine pathway asso-
ciated genes in blood sera and skin biopsies (PAH, PCD, TH, DDC, DBH, 
PNMT, GPX1, MAOA, MAOB, COMT, DRD1-DRD5, VMAT1 and VMAT2) 
and to observe the possible connections to vitiligo pathogenesis. 
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4. MATERIALS AND METHODS 
4.1. Ethical considerations 
The protocols and informed consent forms used in all studies were approved by 
the Ethical Review Committee on Human Research of the University of Tartu. 
All the participants signed a written informed consent. 
 
 
4.2. Characteristics of study participants 
All the patients and control subjects of these studies were Caucasians living in 
Estonia. Unrelated patients with vitiligo from the Department of Dermatology 
at the University of Tartu were included. The diagnosis of vitiligo was based on 
the following clinical signs – loss of pigmentation with typical localization and 
white colour on the skin lesions under Wood’s lamp. All the patients included 
in this study have vitiligo vulgaris and none of them had received specific 
therapy in the previous six months. Patients were classified as having active 
vitiligo if new areas of depigmentation were observed during the previous 3 
months and as stable if no new depigmentation or enlargement of depigmen-
tation had been observed for more than 3 months. The control group consisted 
of volunteers free from a positive family history of vitiligo and other chronic 
dermatoses. The control subjects were recruited from among health care per-
sonnel and medical students and patients present at the dermatological out-
patient clinic with either facial teleangiectasis or skin tags. The main charac-
teristics of the participants in all three studies are presented in Table 2–4. 
 
Table 2. Main characteristics of the participants in the study “Analysis of the expres-
sion profile of CRH-POMC system genes in vitiligo skin biopsies” 
 Total 
number of 
individuals 
Stage of 
vitiligo 
Sex 
female/ 
male 
Average 
age (years)
Mean age 
of vitiligo 
onset 
(years) 
Patients 
with 
family 
history* 
Vitiligo 
patients** 
18 13 active, 
5 stable 
14/4 51.4 27.4 3 
Controls 14 – 12/2 44.9 – – 
Controls 14 – 12/2 44.9 – – 
* The family history of vitiligo is based on the information received from the patients. 
** Thirteen patients in this study have other autoimmune diseases (autoimmune thyroid disease 
(n=5), psoriasis (n=3), rheumatoid arthritis (n=2), pernicious anemia (n=2), and alopecia areata 
(n=1)) 
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Table 3. Main characteristics of the participants in the study “The mRNA expression 
profile of cytokines connected to the regulation of melanocyte functioning in vitiligo 
skin biopsy samples and PBMCs.” 
 SKIN PBMC 
Control Vitiligo 
uninvolved
Vitiligo 
involved
Control Control 
+ L* 
Vitiligo Vitiligo 
+ L* 
Group size 15 15 15 17 17 15 15 
Age range 19–79 19–77 19–77 23–69 23–69 22–69 22–69 
Average 
onset age 
(years) 
– 26.7 26.7 – – 27.4 27.4 
Male/Female 
ratio 
4/11 5/10 5/10 6/11 6/11 5/10 5/10 
Stage of 
vitiligo 
– 9 active, 6 
stable 
9 active, 
6 stable 
– – 12 
active, 
3 stable 
12 
active, 
3 stable 
*L – LPS stimulated PBMCs. Vitiligo is considered to be in an active stage if new lesions 
appeared or the present lesions expanded within three months and in a stable stage if no changes 
occurred within three months.  
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4.3. Analysis of mRNA expression 
4.3.1. Sample collection and RNA extraction  
from skin biopsies and PBMCs 
One skin biopsy (ø 4 mm) from non-sun-exposed skin was taken from control 
subjects. Two skin biopsies (ø 4 mm) were obtained from each patient with 
vitiligo – one from the involved skin and the other from non-sun-exposed un-
involved skin. All biopsies were instantly frozen in liquid nitrogen and stored at 
–80 °C until RNA extraction.  
For total RNA extraction from skin biopsies the RNeasy Fibrous Tissue 
Mini Kit (QIAGEN Sciences, Maryland, USA) was used according to the 
manufacturer’s protocol. Biopsies were homogenized with T10 basic ho-
mogenizer (IKA Labortechnik, Germany). Extracted RNA was dissolved in 
RNase free water and stored at –80 °C until cDNA synthesis. 
Blood was collected from subjects between 8:00 and 12:00 in the morning to 
limit the effect of circadian variation of cytokine production. BD Vacutainer 
CPT tubes (BD, New York, USA) were used to separate PBMCs from other 
blood cells. The cells were centrifuged at 1500 g for 30 minutes at 20 °C. After 
that the blood sera were collected from the top of the PBMCs. PBS (Phosphate 
Buffered Saline) was used to wash the isolated PBMCs twice, after which they 
were centrifuged at 190 g for 10 min at 20 °C. Half of the PBMCs were culti-
vated in the presence of LPS (L2630, Sigma, MO, USA) for 12 hours; and the 
other half was cultivated without LPS stimulation using RPMI-1640 medium 
(PAA Laboratories GmbH, Austria) with 10% Foetal Calf Serum (PAA Labo-
ratories GmbH, Austria) and 1% Pen/Strep (PAA Laboratories GmbH, Austria). 
LPS was used to induce the expression of pro-inflammatory cytokines. [271] 
For RNA extraction from the PBMCs, the TRIzol reagent (Invitrogen Corp., 
Carlsbad, CA, USA) was used according to the manufacturer’s protocol. The 
RNA sediment was dissolved in RNase free water and incubated at 55 °C for 10 
min. The RNA was stored at –80 °C until cDNA synthesis.  
 
 
4.3.2. cDNA synthesis 
For cDNA synthesis, 500 ng of total RNA and High Capacity RNA-to-cDNA 
kit (Applied Biosystems, Foster City, CA, USA) was used. In the case of 
TaqMan® QRT-PCR assays also amplifying genomic DNA (for genes IFNA1, 
IFNB1, IL28A, IL28B and GPX1, DRD1, DRD5) QuantiTect Rev. Transcription 
Kit (QIAGEN Sciences, Maryland, USA) was applied. Both cDNA synthesis 
kits were used according to the manufacturer’s protocol.  
 
 
 
32 
4.3.3. Quantitative real-time polymerase chain  
reaction analysis 
cDNA was used as a template for TaqMan® QRT-PCR analysis in the ABI 
Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, 
CA, USA). Two primers and a labelled probe were used to detect the mRNA 
expression level of the reference gene hypoxanthine phosphoribosyl-transferase 
1 (HPRT1) (HPRT1 exon 6, 5’-GACTTTGCTTTCCTTGGTCAGG-3’; HPRT1 
exon 7, 5’-AGTCTGGCTTATATCCAACACTTCG-3’; VIC-5’- TTTCA-
CCAGCAAGCTTGCGACCTTGA-3’-TAMRA) in all studies. The assays and 
primers used for the studied genes in each study are as follows. 
Analysis of the expression profile of CRH-POMC system genes in 
vitiligo skin biopsies: Two primers and a labelled probe were used for studying 
OPRM1 (Fw, 5’- ATTGGTCTTCCTGTAATGTTCA-3’; Rv, 5’- CAGGTTG-
GATGAGAGAATGTTAGTGT-3; FAM-5’-AGCTACAACAAAATACAGG-
CAAGGTTCCATAGATTG-3’-MGB) [272]; OPRD1 (Fw, 5’-GGGCAAC-
GTGCTTGT-3’; Rv 5’-TCTGGAAAGGCAGCGTG-3’; FAM-5’-ACGGCC-
ACCAACATCTACATCT-3’-MGB); and CRH (Fw, 5’-GCCTCCCATCTCC-
CTGGAT-3’; Rv, 5’-TGTGAGCTTGCTGTGCTAACTG-3’; FAM-5’-TCC-
TCCGGGAAGTCTTGGAAATGGC-3’-MGB) [273] and commercial assays 
for measuring PDYN (Hs00225770_m1), PNOC (Hs00173823_m1), OPRK1 
(Hs00175127_m1), OPRL1 (Hs00173471_m1), CRHR1 (Hs01062290_m1), 
PMCH (Hs00173595_m1), MCHR1 (Hs00538798_m1), ATRN 
(Hs00390610_m1), NURR1 (Hs01118813_m1) mRNA expression. 
The mRNA expression profile of cytokines associated with the regu-
lation of melanocyte function in vitiligo skin biopsy samples and peripheral 
blood mononuclear cells: Two primers and a labelled probe were used to 
detect the mRNA expression level of IL28B (Fw, 5’- AGAGGGCCAAA-
GATGCCTTAG -3’; Rv, 5’- GGGAGCGGCACTTGCA -3; FAM-5’- AGA-
GTCGCTTCTGCTG -3’-MGB). The expression levels of other genes under 
investigation were detected using the following commercial assays: IL20RB 
(Hs00376373_m1), IL22RA2 (Hs00364814_m1), IL26 (Hs00218189_m1), IL28A 
(Hs00820125_g1), IL29 (Hs00601677_g1), IL28RA (Hs00417120_m1), MDM1 
(Hs00220015_m1), IFNA1 (Hs00256882_s1), IFNB1 (Hs01077958_s1), IFNG 
(Hs00989291_m1), ICAM1 (Hs99999152_m1). 
The expression profile of genes associated with the dopamine pathway in 
vitiligo skin biopsies and blood sera: the expression levels of genes under 
investigation were detected using the following commercial assays: PAH 
(Hs00609359_m1), TH (Hs00165941_m1), PCD (Hs00165396_m1), DDC 
(Hs00168031_m1), DBH (Hs01089840_m1), PNMT (Hs00160228_m1), GPX1 
(Hs00829989_gH), MAOA (Hs00165140_m1), MAOB (Hs01106246_m1), 
COMT (Hs00241349_m1), DRD1 (Hs00377719_g1), DRD2 (Hs00241436_m1), 
DRD3 (Hs00364455_m1), DRD4 (Hs00609526_m1), DRD5 (Hs00361234_s1), 
VMAT1 (Hs00915191_m1), VMAT2 (Hs00161858_m1).  
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4.3.4. mRNA expression data analysis 
All reactions were carried out in four replicates. Data are expressed as a mean 
∆CT value relative to HPRT1 ± S.E.M. The results of different groups were 
compared pairwise and no adjustment for multiple testing was performed. 
Adjustment to normal distribution was tested by the Kolmogorov-Smirnov test. 
The data of the studied genes following normal distribution were parametrically 
tested with unpaired t test and the data not following the normal distribution 
with the Mann-Whitney test. During statistical analysis vitiligo patients were 
observed as a whole group or the active and stable form separately. For statis-
tical analysis Microsoft Office 2008 Excel application for Mac (Microsoft Cor-
porate, Redmond, WA, USA) and GraphPad Prism 4 and 5 software (GraphPad 
Software, San Diego, CA, USA) were applied.  
 
 
4.4. Protein level measurements 
4.4.1. Tissue homogenization for protein measurements 
In order to measure protein levels in skin biopsies, the tissue pieces were 
homogenized in PBS buffer including 1 mM ethylenediaminetetraacetic acid 
and 1 mM phenylmethanesulfonylfluoride using Precellys 24 homogenizer with 
the Cryolys system (BERTIN TECHNOLOGIES, Montigny le Bretonneux, 
France). 
 
 
4.4.2. ELISA 
To detect the protein levels of DDC, MAOA, MAOB, DRD1 and DRD5 in 
blood sera and skin biopsie homogenates, commercial ELISA 96-well plate 
ready-to-use kits were applied (Cat. No HU9011, HU9062A, HU9062B, 
HU8296, HU8292, respectively; BIOTANG INC, Waltham, MA, USA). 
 
 
4.4.3. Protein expression data analysis 
Adjustment to normal distribution was tested by the Kolmogorov-Smirnov test. 
The data of all the studied proteins following normal distribution were para-
metrically tested by the unpaired t test and the data not following the normal 
distribution by the Mann-Whitney t test. During statistical analysis vitiligo 
patients were observed as a whole group or the active and stable form sepa-
rately. 
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5. RESULTS  
5.1. Analysis of the expression profile of CRH-POMC 
system genes in vitiligo skin biopsies 
The present study focused on twelve genes (CRH, CRHR1, PMCH, MCHR1, 
ATRN, NURR1, PDYN, PNOC, OPRD1, OPRK1, OPRM1 and OPRL1) asso-
ciated with the CRH-POMC system. The mRNA expression levels were 
measured in punch biopsies of the involved and uninvolved skin of vitiligo 
patients and from the non-sun-exposed skin of healthy subjects. 
 
  
5.1.1. mRNA expression in skin biopsies 
PNOC and its receptor OPRL1 expression levels were 2.99 and 1.83 times 
higher, respectively, in vitiligo involved skin when compared to control skin  
(P < 0.05) (Fig. 5, a and b). The expression of OPRL1 was increased only in the  
 
 
 
Figure 5. Expression levels of PNOC (a), OPRL1 (b), PMCH (c), and MCHR1 (d) in 
skin biopsies by comparison with groups of control subjects (C) and uninvolved (V_UI) 
and involved (V_I) skin of patients with vitiligo. Data are expressed as a mean ∆CT 
value relative to HPRT1 ± S.E.M. * P < 0.05; ** P < 0.01; *** P < 0.001 
C V_UI V_I
0.000
0.005
0.010
0.015
0.020 *
Investigated groups
PN
O
C
 m
R
N
A
 e
xp
re
ss
io
n 
le
ve
l in
 s
ki
n
C V_UI_A V_UI_S V_I_A V_I_S
0.00
0.02
0.04
0.06 **
*
Investigated groups
O
PR
L1
 m
R
N
A
 e
xp
re
ss
io
n 
le
ve
l in
 s
ki
n
a) b)
C V_UI V_I
0.000
0.005
0.010
0.015
0.020
0.025
*
*
***
Investigated groups
M
C
H
R
1 
m
R
N
A
 e
xp
re
ss
io
n 
le
ve
l in
 s
ki
n
C V_UI V_I
0.000
0.001
0.002
0.003
**
**
Investigated groups
PM
C
H
 m
R
N
A
 e
xp
re
ss
io
n 
le
ve
l in
 s
ki
n
c) d)
35 
case of stable form – 2.43 times (P < 0.01). The difference between the active 
and stable form is 1.58 times (P < 0.05). PMCH mRNA expression level was 
increased 1.85 times (P < 0.01) in vitiligo uninvolved skin and 5.36 times  
(P < 0.01) in involved skin compared to control skin (Fig. 5, c). The expression 
level of its receptor gene MCHR1 was 1.6 times higher in vitiligo uninvolved 
skin (P < 0.05) and 2.23 times lower in involved skin (P < 0.05) than in control 
skin (Fig. 5, d). Comparing vitiligo involved and uninvolved skin, the ex-
pression level of MCHR1 differed 3.57 times (P < 0.001) and was higher in 
uninvolved skin. 
PDYN, OPRK1, CRHR1, ATRN, and NURR1 expression levels did not differ 
in vitiligo or control skin samples. The expression levels of OPRD1, OPRM1, 
and CRH mRNA exceeded the detection limit in skin when 125 ng of cDNA 
was used in QRT-PCR reaction; these levels were not sufficient for an accurate 
statistical analysis. 
 
 
5.2. The mRNA expression profile of cytokines 
related to the regulation of melanocyte functioning  
in vitiligo skin biopsy samples and peripheral blood 
mononuclear cells 
This study focused on twelve genes (IL20RB, IL22RA2, IL26, IL28A, IL28B, 
IL29, IL28RA, MDM1, IFNA1, IFNB1, IFNG, and ICAM1) related to immuno-
modulation, melanogenesis, and development and growth of melanocytes. The 
mRNA expression levels were measured in punch biopsies of involved and 
uninvolved skin of vitiligo patients and non-sun-exposed skin of healthy sub-
jects and also in PBMCs (with or without LPS stimulation) derived from 
patients and controls.  
 
 
5.2.1. mRNA expression in skin biopsies and PBMCs 
This study showed that the mRNA expression of IL20RB was in vitiligo un-
involved skin 1.4 times higher (P < 0.01) than in controls (Fig. 6, a). The 
expression was also increased in vitiligo involved skin; however, it is statisti-
cally significant only in the case of stable form (1.5 times (P < 0.05)). In blood 
the mRNA expression of IL20RB was increased in vitiligo patients’ cells when 
compared to controls (32.3 times (P < 0.001) without LPS stimulation and 9.6 
times (P < 0.001) with LPS stimulation) (Fig. 6, b). LPS stimulation decreased 
the IL20RB expression level in vitiligo patients’ PBMCs 4.3 times (P < 0.001); 
this was not found in controls. 
The mRNA expression level of IL22RA2 was 1.5 times higher (P < 0.05) in 
vitiligo uninvolved skin compared to control skin (Fig. 6, c). The expression 
was 1.6 times lower (P < 0.05) in involved skin when compared to uninvolved 
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skin. This effect was observed only in the case of the active stage of vitiligo – 
the IL22RA2 expression was 1.7 times (P < 0.05) higher in controls and 2.7 
times (P < 0.05) higher in uninvolved skin than in involved skin. In PBMCs the 
mRNA level of IL22RA2 was at the detection limit and proper statistical analy-
sis was not possible (data not shown). 
The mRNA expression level of IL26 did not differ significantly in skin when 
comparing patients and controls (data not shown). In PBMCs the mRNA level 
of IL26 was near the detection limit and accurate statistical analysis was not 
possible (data not shown).  
The mRNA expressions of IL28A, IL28B, IL29, and IL28RA were detected 
in skin and in PBMCs; however, the levels were too low for accurate statistical 
analysis in the case of IL28A, IL28B, and IL29 in skin and IL29 in PBMCs (data 
not shown). The mRNA expression level of IL28RA was 1.7 times higher 
(P < 0.01) in vitiligo uninvolved skin compared to controls (Fig. 6, d). IL28A 
mRNA expression was 1.7 times (P < 0.05) lower in patients’ PBMCs 
compared to controls when stimulated with LPS (Fig. 6, e). The mRNA 
expression levels of IL28B and IL28RA did not differ statistically relevantly in 
the PBMCs of vitiligo patients and controls (data not shown). 
The expression level of MDM1 mRNA was 4.2 times (P < 0.001) higher in 
uninvolved and 3.0 times (P < 0.001) higher in involved vitiligo skin when 
compared to controls (Fig. 7, a). In blood the expression of MDM1 was higher 
in patients’ PBMCs – 1.7 times (P < 0.01) without LPS stimulation and 1.5 
times (P < 0.01) with LPS stimulation (Fig. 7, b). 
In the skin the IFNA1 mRNA expression level was too low for accurate sta-
tistical analysis (data not shown). In blood the expression level of IFNA1 was 
4.8 times (P < 0.05) higher in patients’ PBMCs compared to control cells (Fig. 
7, c). In the case of the stable form IFNA1 expression was even 7.3 (P < 0.05) 
and 9.0 times (P < 0.01) higher without or with LPS stimulation, respectively. 
The increase was not statistically relevant with the active form. 
The mRNA expression of IFNB1 was 4.5 times (P < 0.05) higher in vitiligo 
uninvolved skin compared to control skin (Fig. 7, d) and 2.9 times (P < 0.05) 
higher in patients’ PBMCs than in the cells of the controls (Fig. 7, e). In the 
case of the stable form, the expression in blood cells was 3.4 times (P < 0.01) 
higher without LPS stimulation and 3.0 times (P < 0.05) higher with LPS 
stimulation. The increase was not statistically relevant with the active form.  
The mRNA expression of IFNG was 3.9 times higher (P < 0.05) in vitiligo 
involved skin than in control skin (Fig. 7, f). IFNG expression was higher in 
patients’ PBMCs compared to controls without or with LPS stimulation (3.5 
times (P < 0.01) and 3.3 times (P < 0.01), respectively) (Fig. 7, g). 
ICAM1 mRNA expression was higher in both uninvolved and involved 
vitiligo skin (1.7 times (P < 0.01) and 1.4 times (P < 0.05), respectively) by 
comparison with control skin (Fig. 7, h). ICAM1 mRNA expression at the stable 
stage had decreased in involved skin compared to uninvolved skin (1.7 times 
(P < 0.01)); this pattern did not occur at the active stage. The mRNA expression 
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of ICAM1 was at the same level in the PBMCs of patients and controls (data not 
shown). 
 
 
 
 
 
 
 
Figure 6. mRNA expression levels of genes associated with IL10 family cytokines in 
vitiligo patients’ uninvolved (UI) and involved (I) skin and the skin of controls (C) and 
patients (V) and controls (C) PBMCs with (L) or without LPS stimulation. Additionally, 
patients were divided into subgroups with the active (A) and stable (S) forms of vitiligo. 
Data are expressed as a mean ∆CT value relative to HPRT1 ± S.E.M. * P < 0.05;  
** P < 0.01; *** P < 0.001 
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Figure 7. mRNA expression levels of genes possibly regulating the functioning of 
melanocytes in the uninvolved (UI) and involved (I) skin of vitiligo patients and the 
skin of controls (C) and in the PBMCs of patients (V) and controls (C) with (L) or 
without LPS stimulation. Additionally, the patients were divided into subgroups with 
the active (A) and stable (S) forms of vitiligo. Data are expressed as a mean ∆CT value 
relative to HPRT1 ± S.E.M. * P < 0.05; ** P < 0.01; *** P < 0.001 
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5.3. The expression profile of genes associated  
with the dopamine pathway in vitiligo skin  
biopsies and blood sera  
To study the possible associations between vitiligo and genes in dopamine 
pathway, the mRNA expression levels of seventeen genes (PAH, PCD, TH, 
DDC, DBH, PNMT, GPX1, MAOA, MAOB, COMT, DRD1-DRD5, VMAT1, and 
VMAT2) were measured in punch biopsies from the involved and uninvolved 
skin of vitiligo patients and from the non-sun-exposed skin of control subjects. 
Subsequently, the protein levels of five genes were measured in homogenates of 
skin biopsies and blood sera. DDC, MAOA, DRD1, and DRD5 were chosen 
while their mRNA expression level in the skin differentiated between patients 
and controls; also MAOB was included while the latter is sequentially and 
functionally similar to MAOA. The protein level of other genes was not ana-
lysed due to the limited amount of biopsy material available. 
 
 
5.3.1. mRNA expression in skin biopsies 
We were able to detect PAH and TH mRNA in skin biopsies; however, the 
levels were too low for accurate statistical analysis. The mRNA expression of 
PCD, DBH, and PNMT did not differ significantly between vitiligo and control 
skin. The mRNA expression of DDC was 5.2 times lower (P < 0.05) in un-
involved and 7.6 times lower (P < 0.05) in involved vitiligo skin by comparison 
with control skin (Fig 8. A). 
mRNA expression level of GPX1 has a tendency to increase in vitiligo skin 
compared to control skin. The difference was significant only in the case of 
involved skin of patients with stable vitiligo – 2.7 times higher (P < 0.05) 
compared to control skin. Furthermore, GPX1 mRNA level increased 2.7 times 
(P < 0.01) in the involved skin of patients with stable vitiligo compared to 
patients with the active form (Fig 8. B). The expression level of MAOA mRNA 
was higher in the skin of vitiligo patients than in controls – in uninvolved skin 
the difference was significant only in the case of the stable form (1.8 times; 
P < 0.05); in involved skin the differences were 2.5 times (P < 0.001) and 2.2 
times (P < 0.05) in patients with active and stable vitiligo, respectively 
(Fig 8. C). In the case of MAOB (Fig 8. D) and COMT, the mRNA expression 
levels did not differ between vitiligo skin and controls.  
DRD1 and DRD5 mRNA expression levels were higher in vitiligo skin com-
pared to controls. In uninvolved skin the DRD1 expression was elevated 4.2 
times (P < 0.001) and DRD5 1.9 (P < 0.01) times (Fig 8. E and 8. F). In 
involved skin the difference from controls was significant only in the case of 
DRD1 (3.2 times; P < 0.05). The expression level of DRD2 did not differ when 
controls and vitiligo patients were compared. mRNA expression of DRD3 and 
DRD4 was detected in skin; however, the expression level was too low for 
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accurate statistical analysis. The mRNA expression levels of VMAT1 and 
VMAT2 were equivalent in the skin samples of controls and vitiligo patients. 
 
 
 
Figure 8. mRNA expression of the studied genes in the uninvolved (UI) and involved 
(I) skin of vitiligo patients and controls (C). Additionally, the groups of vitiligo patients 
with uninvolved skin and involved skin were divided into subgroups of patients with the 
active (A) and stable (S) forms of vitiligo. Data are expressed as a mean ∆CT value 
relative to HPRT1 ± S.E.M. * P < 0.05; ** P < 0.01; *** P < 0.001 
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5.3.2. Protein expression level in skin biopsies 
The protein levels of all five genes (DDC, MAOA, MAOB, DRD1, DRD5) were 
different in controls and involved and uninvolved skin of vitiligo patients.  
The expression of DDC protein was higher in vitiligo skin than in controls – 
the difference was statistically significant in uninvolved and involved skin of 
patients with active vitiligo (2.7 times; P < 0.05 and 1.8 times; P < 0.05, respec-
tively). It was reflected also in the whole group of involved skin – the dif-
ference amounted to 1.9 times (P < 0.05) (Fig 9. A). 
The protein levels of MAOA and MAOB increased in vitiligo patients com-
pared to controls. In patients with active vitiligo the MAOA protein level is 2.8 
times (P < 0.05) and 1.8 times (P < 0.05) higher in uninvolved and involved 
skin, respectively (Fig 9. B). The effect can also be seen in whole groups: it is 
2.4 times (P < 0.05) and 1.9 times (P < 0.05) higher in vitiligo uninvolved and 
involved skin, respectively. The MAOB level is 2.7 times (P < 0.05) higher in 
uninvolved and 2.0 times (P < 0.05) higher in the involved skin of patients with 
active vitiligo (Fig 9. C). When observing whole groups: MAOB protein 
expression is 2.4 times (P < 0.05) higher in uninvolved and 2.1 times (P < 0.01) 
higher in the involved skin of vitiligo patients compared to controls. 
Both DRD1 and DRD5 protein expression levels are higher in vitiligo skin 
than in controls. The level of DRD1 protein is 2.6 times (P < 0.05) higher in 
uninvolved and 1.8 times (P < 0.05) higher in the involved skin of patients with 
active vitiligo (Fig 9. D). It is reflected also in the whole group of involved 
skin – the protein level is 1.8 times (P < 0.05) higher. The DRD5 protein level 
increased 3.0 times (P < 0.01) in uninvolved skin and 2.1 times (P < 0.05) in the 
involved skin of patients with active vitiligo (Fig 9. E). The effect can be seen 
also in whole groups – the protein level is 2.6 times (P < 0.05) higher in vitiligo 
uninvolved and 2.2 times (P < 0.05) higher in involved skin compared to 
controls. 
 
 
5.3.3. Protein expression level in blood sera 
The protein level of DDC, MAOA, MAOB, and DRD5 did not differ statisti-
cally relevantly in the sera obtained from the blood of controls and vitiligo 
patients. The expression of DRD1 protein decreased 1.4 times  
(P < 0.01) in patients’ sera compared to controls (Fig 9. F). 
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Figure 9. Protein expression of the studied genes in the uninvolved (UI) and involved 
(I) skin of vitiligo patients and controls (C), also in patients (V) and controls (C) blood 
sera. Additionally, different patient groups of skin and blood serum studies were 
divided into subgroups of patients with the active (A) and stable (S) forms of vitiligo. 
The columns show mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001 
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6. DISCUSSION  
6.1. Analysis of the expression profile of CRH-POMC 
system genes in vitiligo skin biopsies 
Vitiligo is a pigmentation disorder and the mechanisms leading to it are still not 
completely understood. The associations between vitiligo pathogenesis and the 
CRH-POMC system are becoming more and more evident. [160, 172] The pre-
sent study focused on possible interactions between vitiligo and neuropeptides 
and their receptors related to the CRH-POMC system. For that purpose, twelve 
different genes were studied – CRH, CRHR1, PMCH, MCHR1, ATRN, NURR1, 
PDYN, PNOC, OPRM1, OPRD1, OPRK1, and OPRL1 (Table 5).  
 
Table 5. Expression level of the POMC-CRH-MCH pathway and other endogenous 
opioid associated genes in the skin. Data combined from our previous and present 
studies. [138] The mRNA levels of the studied genes in vitiligo patients compared to 
controls.  – expression in vitiligo patients has increased;  – expression in vitiligo 
patients has decreased;  – expression is not significantly different between patients 
and controls;  – expression was not observed; ND – expression was not detected; 
NDL – expression was near detection limit, statistical analysis not performed.  
* P < 0.05; ** P < 0.01; – P > 0.05. 
 
 mRNA in skin 
 Uninvolved skin Involved skin 
Gene 
name active stable active stable 
POMC  * 
MC1R ** – 
MC2R – – 
MC3R – – 
MC4R ** – 
MC5R – – 
ASIP  
AGRP  
CRH NDL NDL 
CRHR1  
PMCH ** ** 
MCHR1 * * 
PDYN  
PNOC  * 
OPRM1 NDL NDL 
OPRD1 NDL NDL 
ORRK1  
OPRL1   ** 
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The present study shows that in involved vitiligo skin the expression of PNOC 
mRNA has increased significantly compared to control skin. Furthermore, the 
level of its receptor OPRL1 mRNA expression increased relevantly in the 
involved skin of patients with stable vitiligo compared to control samples, 
which indicates the activation of this opioid-related system in vitiligo skin. The 
PNOC system has not been studied properly and possible associations between 
the PNOC system and vitiligo pathogenesis have not been observed previously. 
A study was published, where Staphylococcal enterotoxin A, which activates  
T-cells, was injected into male mice and it caused an increase in the PNOC 
mRNA expression level in the brain. [274] According to another study, 
nociceptin acting through OPRL1 receptors inhibits components of neurogenic 
inflammation in rat skin. [275] It has also been reported that nociceptin may in 
different conditions either stimulate or inhibit the proliferation and activation of 
T cells. [276] Hence, this system could participate in inhibiting the progression 
of lesions; PNOC and OPRL1 could have a substantial immunomodulatory role 
in skin as well in the nervous system and may be associated with the inflam-
mation common to vitiligo.  
The present study indicates that the mRNA expression level of MCH is 
detectable in skin although previous studies using reverse transcription-PCR 
detected MCH expression in the endothelial cells of cultured skin, but not in the 
entire skin or cultured melanocytes, keratinocytes, or fibroblasts. [168] One 
possibility is that mRNA of PMCH is derived from macrophages. [277] By 
comparison with control skin, the mRNA expression of PMCH was increased 
both in uninvolved and involved vitiligo skin. The considerable accumulation of 
MCH found in vitiligo involved skin contributes to the previous finding that 
MCH inhibits the melanogenic action of αMSH. [172]  
Measuring the level of MCHR1 in different groups indicated that the expres-
sion is upregulated in uninvolved vitiligo skin and down-regulated in involved 
skin when compared to control skin. In the literature there is no information 
about the expression level of MCHR1 in vitiligo skin compared to control skin. 
However, as noted, autoantibodies against MCHR1 have been found in the sera 
of vitiligo patients. [171] Melanocytes have been found to be the only skin cells 
expressing MCHR1 [168], and vitiligo involved skin has fewer or no melano-
cytes, which explains the lower MCHR1 expression level. The increase of 
MCHR1 expression in uninvolved vitiligo skin is probably connected to the 
antagonizing mechanism of the POMC system and could be a part of the ini-
tiating process of the reduction of melanogenesis and destruction of melano-
cytes. However, further studies are needed to confirm how exactly MCH with 
its receptors and the CRH-POMC system are associated in skin. 
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6.2. THE mRNA expression profile of cytokines 
associated with the regulation of melanocyte 
functioning in vitiligo skin biopsy samples and 
peripheral blood mononuclear cells 
Several cytokines have been suggested to participate in vitiligo pathogenesis. 
The present study assessed the importance of cytokines and their receptors and 
a few other genes connected to IL10 family cytokines and possibly involved in 
the regulation of the development and survival of melanocytes and melano-
genesis. [181–186] See Table 6 for a better overview of our previous and 
present studies about IL10 family cytokines and their receptors in the skin and 
blood samples of vitiligo patients. 
In addition to our previous studies, the present study revealed supplemental 
changes in the expression of cytokines and receptor genes associated with the 
IL10 cytokine family. The IL20RB mRNA level was higher in the skin samples 
of vitiligo patients. Previous work indicated that the IL20RA expression level 
decreased and the IL22RA1 mRNA level remained the same in vitiligo skin 
compared to control skin. Ligands for these receptor complexes – IL19, IL20 
and IL24 were not detected in the skin when QRT-PCR was used. [195] Here 
the increased IL20RB level may occur due to a compensating mechanism, 
which tries to retain the normal amount of the IL20RA-IL20RB complex; 
however, further studies are needed to see how the mechanism works in the 
skin.  
As in the skin, the IL20RB mRNA level was also higher in patients’ PBMCs 
compared to control cells. We have demonstrated earlier that the mRNA 
expression level of IL20RA and IL22RA1 are near detection limit in PBMCs 
when using QRT-PCR. The IL19 mRNA expression increased; the IL20 mRNA 
and protein levels have a tendency to decrease, and IL24 mRNA expression 
remains the same in vitiligo patients’ blood compared to controls. [195] The 
increased expression level of IL20RB in PBMCs may be somehow associated 
with the higher levels in the skin, while the regulation mechanism could be 
similar locally and systemically.  
IL22RA2 (antagonizing IL22 receptor complex) mRNA expression level 
decreased in involved vitiligo skin comparing to uninvolved vitiligo skin and 
control skin – these changes appear only in the case of active vitiligo. We have 
showed earlier that IL22 expression increased significantly in patients’ PBMCs 
(these changes occur only at the active stage of vitiligo), and also the protein 
level is higher in patients’ blood sera comparing to controls. [195] IL22 recep-
tor complex genes IL22RA1 and IL10RB expression levels are at the same level 
in the skin of patients and controls. [195] Thus, it is possible that a certain level 
of IL22RA2 is essential for binding the excess of IL22; and in the case of the 
active stage of vitiligo the lack of IL22RA2 may possibly lead to inflammation 
and thereby destruction of melanocytes.  
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Table 6. Expression level of IL10 cytokine family associated genes. Data combined 
from our previous and present studies. [37] The mRNA and protein levels of the studied 
genes in vitiligo patients compared to controls.  – expression in vitiligo patients has 
increased;  – expression in vitiligo patients has decreased;  – expression is not sig-
nificantly different between patients and controls;  – expression was not observed; 
ND – expression was not detected; NDL – expression was near detection limit, statis-
tical analysis not performed. * P < 0.05; ** P < 0.01; ***P < 0.001; – P > 0.05. 
 mRNA in skin mRNA in PBMCs Protein in blood sera 
 Uninvolved 
skin Involved skin
Vitiligo Vitiligo + 
LPS 
Vitiligo blood 
sera 
Gene 
name 
Active Stable Active Stable Active Stable Active Stable Active Stable 
IL10 ND – – 
IL19 
isoform 1 
ND ND  
IL19 
isoform 2 
ND *  *   
IL20 ND – – 
IL22 ND **  –  *** 
IL24 ND  *  
IL26    NDL  
IL28A   NDL – *  
IL28B   NDL   
IL29   NDL   NDL  
IL10RA – ***  
IL10RB  ***   
IL20RA ** ND  
IL20RB **  * ***  
IL22RA1 
(IL22RA) 
 ND  
IL22RA2 
(IL22RB) 
* * – NDL  
IL28RA ** –   
 
 
It is known that IL20 and IL22 have similar functions – preventing terminal 
differentiation of keratinocytes and upregulating antimicrobial peptides to pro-
tect epithelial surface from invading pathogens. [278, 279] IL22 has been 
shown to induce the expression of IL20 and they also share one receptor 
subunit – IL22RA1, which is expressed similarly in the skin of controls and 
vitiligo patients. [189, 195, 279] According to previous findings, the IL20 and 
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IL22 are both upregulated in the skin of psoriasis patients and the blood levels 
correlate with the significance of the disease. [279–281] In the case of vitiligo 
the expression pattern of IL20 and IL22 is dissimilar – IL20 expression has a 
tendency to decrease and IL22 expression increased in patients’ PBMCs and no 
expression is detected in the skin. [195] The receptors expression pattern does 
not match either. [195, 282] This indicates that in the case of various auto-
immune diseases associated with skin, the IL20 and IL22 may act differently, 
the regulation methods may be dissimilar, and thus, the effect on skin cells 
varies.  
The mRNA expression level of IL28A decreased in vitiligo patients’ PBMCs 
and IL28B expression has a tendency to increase in patients’ PBMCs (statisti-
cally insignificant) when comparing to controls. IL28A, IL28B, and IL29 
mRNA levels are near detection limit in the skin. IL28RA expression is higher 
in patients’ uninvolved skin compared to controls and has a tendency to 
decrease in involved skin. Our previous studies showed that the mRNA expres-
sion of IL10RB, which together with IL28RA constructs a receptor complex for 
IL28A, IL28B, and IL29, increased significantly in vitiligo patients’ PBMCs 
compared to controls; however, the level remained uniform in the skin. [195] It 
has been shown that both epidermal melanocytes and keratinocytes are major 
targets for IL28A, IL28B, and IL29. [283] Maturing dendritic cells and regu-
latory T cells may produce these cytokines; growth inhibition has been demon-
strated in the case of keratinocytes. [62] The results of our study indicate the 
possibility that IL28A, IL28B, and IL29 could participate in vitiligo patho-
genesis and could possibly influence also the proliferation of melanocytes. 
These cytokines and their receptor subunits should be studied further to achieve 
more confident implications.  
A major finding in the case of IL10 family cytokines and their receptors is 
the controversial effects of LPS stimulation. In previous and present studies we 
have observed LPS stimulation in the case of PBMCs derived from patients and 
controls. [195] The LPS affects differently the mRNA expression levels of IL20 
(a tendency to increase in controls, a similar level in patients), IL22 (an increase 
in controls, a tendency to decrease in patients), IL24 (a tendency to increase in 
controls, a tendency to decrease in patients; a significant decrease of IL24 
mRNA expression appears only in the case of LPS stimulation), IL10RB (the 
level remains the same in controls, an increased level in patients decreases to 
the control level) and IL20RB (a similar level in controls, a decreased level in 
patients). LPS is recognized by toll-like receptor 4 (TLR4), which further 
induces the production of proinflammatory cytokines to create the innate 
immune response. [284] Our findings may imply that in the case of vilitigo 
pathogenesis, in addition to the adaptive immune system, the innate immune 
response is somehow involved. Another finding is that the altered innate 
immune response may lead to the activation of autoimmunity, which was 
proven in the case of vitiligo. [285] 
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The present work demonstrated that MDM1 mRNA expression is higher in 
vitiligo patients’ skin and PBMCs when compared to controls. MDM1 (located 
near IL22 and IL26 on chromosome 12) may have a common expression regu-
lation mechanism with IL22, while both are upregulated in patients’ PBMCs. 
[195] The function of MDM1 is still unknown; its connections to oncogenic 
processes, transcriptional machinery, and iron management have been sug-
gested. [224, 225, 286, 287] Our work demonstrates that MDM1 is possibly 
related to vitiligo pathogenesis and needs further analysis. Additional support to 
its role in melanocyte survival comes from a recent study where MDM1 mutant 
mice exhibited pigmentary abnormalities and had an increased number of 
phagosomes in retinal pigment epithelium. [288] 
The expression profiles of IFNA and IFNB were also changed – IFNA1 and 
IFNB1 mRNA expression were higher in vitiligo patients’ PBMCs (especially 
in the case of stable form) compared to controls; IFNB1 expression increased 
significantly in vitiligo uninvolved skin. Previously it has been demonstrated 
that IFNA and IFNB subcutaneous treatment could cause vitiligo. [230, 234, 
235] The mechanism could move through both the innate and adaptive immune-
system pathways while IFNA and IFNB as important agents against viral in-
fection are also able to affect T and B cells. [230, 231, 233] Our findings sug-
gest that vitiligo could be triggered also by the inner changes (both local and 
systemic) of the expression patterns of these interferons. The fact that the 
mRNA levels are even higher in the stable stage of vitiligo implies the possi-
bility that IFNA and IFNB may participate in maintaining the depigmented 
lesions.  
Our study confirmed that the IFNG mRNA expression level increased sig-
nificantly in patients’ involved skin and also in PBMCs compared to controls. 
ICAM1 mRNA expression increased in both uninvolved and involved vitiligo 
skin compared to controls. Furthermore, in patients with stable vitiligo the 
ICAM1 expression decreased in involved skin compared to uninvolved skin, 
which did not occur in the case of patients with active vitiligo. These results are 
supported by previous findings – in vitiligo skin, the amount of cytotoxic T 
cells increased, which is probably due to an increased level of leukocytes 
recruiting ICAM1 and its expression stimulating agent IFNG. [244, 245, 289] 
Thus, ICAM1 is probably an important link between cytokines and T cells 
involved in vitiligo pathogenesis. The reason why the ICAM1 mRNA level has 
a tendency to decrease in involved skin compared to uninvolved skin of stable 
vitiligo could be in the loss of melanocytes in depigmented areas. On the other 
hand, the epidermal cells express more ICAM1 than they should at the active 
stage of vitiligo, which leads to already proven T cell activation in vitiligo skin. 
[290] However, further research is needed. 
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6.3. The expression profile of genes associated  
with the dopamine pathway in vitiligo skin  
biopsies and blood sera 
Melanogenesis can be initiated from either L-Phe or L-Tyr, which are 
hydroxylated to L-DOPA. The latter serves as a precursor for melanins and 
catecholamines, which both are synthesized in skin via separate pathways. 
These pathways share several enzymes, cofactors and are competitive on certain 
levels. [250] It has been shown that the levels of dopamine, norepinephrine, 
epinephrine, and their metabolites have increased in vitiligo patients’ plasma 
and urine. [34, 39, 40] The increase in the catecholamine level even suggests 
that it might be an initiating event of vitiligo pathogenesis. [291] Thus, only 
dopamine has been proven to have an apoptotic effect on melanocytes, most 
probably while increasing the reactive oxygen species level in cells. [292, 293] 
Our study revealed that the expression profile of several genes connected to 
the dopamine pathway has altered in vitiligo skin (Table 7). In the case of 
enzymes in the catecholamine synthesis pathway the DDC (essential to produce 
dopamine from L-DOPA) mRNA level decreased in patients’ skin, which 
correlates with the findings that the protein level in epidermis is significantly 
lower, and the serotonin and melatonin levels have decreased. [261] Though, 
the findings of our study contradict the previous studies of mRNA expression 
and protein – the DDC protein level in vitiligo skin increased. However, the 
latter supports the fact that the level of dopamine increased in patients. [34, 39, 
40] DDC is important for both dopamine and serotonin production, and these 
controversial results need additional studies; the present data do not enable us to 
make any further conclusions. 
The studies of the activity of H2O2 degrading enzyme GPX1 in vitiligo 
patients have yielded controversial results – the activity has been higher, lower, 
or similar comparing to the blood and skin of controls. [265, 294–300] Our 
study found that the mRNA expression of GPX1 has a tendency to increase in 
patients’ uninvolved skin compared to controls. On the other hand, we showed 
that the GPX1 mRNA level was at the same level in controls and involved skin 
of patients with active vitiligo; however, the level is significantly higher in the 
involved skin of patients with the stable form. These results correlate with the 
previous results, where among active vitiligo cases only 4% of the studied 
individuals had an increased GPX1 activity; however, in stable cases 20% had a 
higher GPX1 activity. [295] The increased transcription of GPX1 may some-
how be involved in inhibiting the progression of the disease; however, the dif-
ferences between the active and stable forms needs further analysis.  
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Table 7. The mRNA and protein levels of the studied genes in vitiligo patients com-
pared to controls.  – expression in vitiligo patients has increased;  – expression in 
vitiligo patients has decreased;  – expression is not significantly different between 
patients and controls;  – expression was not observed. * P < 0.05; ** P < 0.01; ***P 
< 0.001. 
 mRNA in skin Protein in skin Protein in blood sera 
 Uninvolved skin 
Involved skin Uninvolved 
skin 
Involved skin Vitiligo blood 
sera 
Gene 
name 
active stable active stable active stable active stable active stable 
DDC * * *  *   
GPX1   *   
MAOA  * *** *  *   
MAOB   *  *   
DRD1 *** * *  *  ** 
DRD5 **  **  *   
 
 
The activity of catecholamine degrading enzymes COMT and MAOA has 
previously been demonstrated to be higher in vitiligo skin. [251, 252] We found 
that the mRNA expression of COMT was similar in the skin of vitiligo patients 
and controls, which may indicate the possibility that the increased activity is 
due to the changes in the protein level. In the case of MAOA and MAOB we 
found that the mRNA level of MAOA was higher in patients’ skin compared to 
controls; the MAOB mRNA expression level did not differ significantly 
between the groups. Both MAOA and MAOB protein levels were higher in 
patients’ uninvolved and involved skin. Our results support the previous 
findings that the activity of MAOA increased in patients’ skin compared to 
controls. [251] While MAOA and MAOB equally metabolize dopamine, one 
might suggest that MAOB activity also increases in vitiligo skin, which needs 
to be confirmed. The fact that in vitiligo uninvolved skin the protein levels of 
MAOA and MAOB increased at the active stage compared to the stable form, 
may imply an attempt to reduce the dopamine level in the skin while new 
patches are developing on the skin.  
Dopamine has five receptors (DRD1-DRD5) of which DRD1, DRD2, and 
DRD4 have been demonstrated to participate in the regulation of melano-
genesis. [268–270] DRD1 and DRD5 both belong to the D1- like family; they 
activate adenylyl cyclase, which increases the intracellular cAMP level. The 
cAMP/PKA pathway is the main pathway through which melanogenesis 
enzymes can be reached, and it is used by melanocortins to modulate melano-
genesis. [5, 301, 302] In addition to activating the cAMP/PKA pathway, both 
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dopamine receptors and melanocortin receptors have a similar expression 
pattern in vitiligo skin – our present and previous studies showed that the levels 
of MC1R and MC4R mRNA and dopamine D1-like family receptors’ mRNA 
and protein increased in uninvolved skin and again decreased in the involved 
skin of vitiligo patients. [138] The mRNA expression of POMC decreased and 
the level of dopamine increased in involved vitiligo skin. [35, 303] Fur-
thermore, previous studies demonstrated that MSH binds to DRD1 and in-
hibits the attachment of the ligand – in the presence of both MSH and dopa-
mine the cAMP level decreased compared to the presence of these two media-
tors separately (indicated in the brain). [267] There is also data that MSH 
might increase the dopamine level in nucleus accumbens through MC4R. [246] 
We did not find any data in the literature about dopamine binding or affecting 
the melanocortin receptors directly. We have suggested previously that the up-
regulation of the melanocortin system in vitiligo uninvolved skin is relevant to 
compensation of the loss of pigment in involved skin. [35] Nevertheless, the 
major challenge is to find out how exactly melanocortin and dopamine path-
ways are connected to each other while regulating melanogenesis in the skin 
and participating in vitiligo pathogenesis.  
When observing from a different perspetive, it has been demonstrated that 
the level of dopamine and its metabolites increased in vitiligo patients’ skin, 
urine, and peripheral blood. [34, 39, 264] In the case of DRD1 it has been 
shown that dopamine stimulates the DRD1 promoter and thereby mRNA 
expression. [304] Furthermore, dopamine acts on DRD1, which causes the 
negative feedback and a decrease in dopamine release (demonstrated in the 
brain). [305] In vitiligo uninvolved skin the elevation of D1-like receptors may 
also be caused by the increased level of dopamine in patients. Furthermore, the 
decrease of D1-like receptor expression in involved skin may be caused by the 
negative feedback pathway. However, these suggestions need further studies 
and more supportive evidence.  
Our study showed that the DRD1 protein level decreased in patients’ blood 
sera compared to controls. When dopamine activates D1-like receptors on 
regulatory T cells, they are less able to suppress the proliferation of effector T 
cells. Activated effector T cells increase the synthesis of cytokines and adhesion 
molecules and affect different target cells. [306] In vitiligo patients the decrease 
of DRD1 protein in blood sera may point to a possible compensating mecha-
nism – an attempt to decrease the elevated level of activated effector T cells in 
the organism. Nevertheless, additional studies are required. 
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6.4. Local HPA axis in vitiligo skin 
The main adaptive responses to systemic stress are mediated by the HPA axis. 
[9] Activation of this pathway proceeds through the hypothalamic production of 
CRH, which stimulates CRHR1 in pituitary. Anterior pituitary-derived POMC 
peptides activate the MC2R receptors in the adrenal gland and cortisol is re-
leased. The HPA axis is suppressed through negative feedback via cortisol re-
ceptors in hypothalamus and pituitary. [9–12, 104] 
Skin expresses the neuroendocrine system using mediators similar to those 
involved in the classical endocrine systems at the brain and pituitary levels 
(CRH, URC, and POMC derived peptides); furthermore, skin cells express 
functional receptors activated by different neuropeptides. [1, 104, 307–309] 
Local effectors of this axis would regulate the pigmentary, immune, epidermal, 
dermal, and adnexal systems of the skin. Accordingly, physical stress (UV 
light) or biological or chemical stress would trigger multiple pathways in-
volving structuralized or simultaneous local production of CRH, CRH-related 
peptides, and POMC derived messages. [86, 104] This complex response would 
be susceptible to heterotrophic modulation through feedback inhibition by cor-
tisol. Thus, by analogy with the central axis, stress would stimulate the pro-
duction and secretion of ACTH of cutaneous origin, which would further 
increase the level of glucocorticoids – recognized inhibitors of the immune 
system. [96]  
In the case of vitiligo the mechanisms, which should ensure the homeostasis 
in the skin, have altered. In our studies, we observed different agents partici-
pating in cutaneous HPA axis. When moving along the signal cascade of the 
classical HPA axis the first agent is CRH, which through CRHR1 participates in 
cell proliferation, apoptosis, differentiation, and immune activities in the skin. 
[101, 103, 108, 310, 311] Our studies did not reveal any differences in CRH or 
its receptor CRHR1 mRNA expression in vitiligo skin compared to control skin. 
CRH, which is produced in skin cells, is also suggested to be released from 
peripheral nerve endings. [312] The factors that have been demonstrated to 
affect the expression of CRH and CRHR1 in the skin are UV radiation and an 
increased intracellular cAMP level. [162, 313, 314] Thus, in vitiligo patients, it 
is possible that the CRH system may have remained normal, and the effects are 
due to the further agents of this cascade. 
Activated CRHR1 should stimulate the expression of POMC and the pro-
duction of MSH, ACTH, and -endorphin, which are essential regulators of 
melanogenesis and survival of the melanocytes. [162–166] In vitiligo involved 
skin, the POMC mRNA expression level is significantly lower compared to 
uninvolved skin, and the mRNA expression level of MC1R and MC4R has 
decreased in involved skin comparing to uninvolved skin. However, the expres-
sion is evidently higher in uninvolved skin than in the skin of controls. [138] 
Studies from other groups showed that the MSH level had decreased in 
patients’ skin and sera. [315] The level of ACTH increased in vitiligo patients’ 
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skin and plasma. [316, 317] The levels of -endorphin in patients’ plasma and 
tissue fluids from skin lesions increased, which could be an attempt to maintain 
the melanogenesis and number of melanocytes. [318, 319] Also, the met-
enkephalin levels increased in patients’ plasma. [160] The increased level of 
POMC-derived peptides could be explained by a systemic increase while 
locally the POMC expression decreased.  
The decreased MSH levels may be one of the reasons for higher in-
flammatory signals (IL1, IL6, IL8, IL22, and TNFA) and activation of adhesion 
molecules (ICAM1), as well as decreased IL10 levels in vitiligo patients. [36–
38, 41] The causes of changed POMC and its derivates and also receptor levels 
may be different. In vitiligo skin the increased H2O2 level leads to the oxidation 
of epidermal ACTH, MSH, and -endorphin. In the case of -endorphin it is 
known to lose its ability to induce melanogenesis. [320] The MC1R has been 
found to be expressed only in melanocytes, which explains the decrease in 
lesional skin. [37, 321] Β-endorphin possibly stimulates the proliferation of 
melanocytes through OPRM1 [146, 147]. However, we were unable to evaluate 
the possible changes in OPRM1 mRNA expression levels in the skin. Addi-
tionally, the increased expression of MCH and its receptor MCHR1 seem to 
inhibit the further signal pathway of MSH in patients’ skin. [171] Thus, the 
expression pattern and activity of genes associated with the POMC system have 
severely changed in the case of vitiligo pathogenesis, which may lead to the 
destruction of melanocytes.  
In addition to the melanocortin system, the system of another endogenous 
opioid PNOC and its receptor OPRL1, have a potential role in maintaining the 
normal functioning of the inflammatory mechanisms in the skin. [275, 276] In 
vitiligo patients’ skin, the activation of the PNOC system may not be sufficient 
to inhibit the increased inflammatory signals. [36–38] Thus, it may be a part of 
a cutaneous HPA axis regulation mechanism.  
The next agents in the HPA axis are glycocorticoids, which are produced by 
melanocytes, fibroblast, and hair follicle keratinocytes. [107, 109] Gluco-
corticoid receptors are ligand-dependent transcription factors, which are highly 
expressed in keratinocytes, fibroblasts, and Langerhans cells and less expressed 
in melanocytes. [322] In vitiligo patients the cortisol levels in serum have not 
changed by comparison with controls. [160] So far there is no information 
about GR expression in vitiligo patients. However, glucocorticoids (corti-
costeroids) are used as immunosuppressive and anti-inflammatory agents in 
vitiligo therapy and repigmentation occurs. Combined with UV therapy, it 
induces the apoptosis of skin-infiltrating T cells and reduces the melanocyte 
associated antigen level. [323–326] Thus, according to the available data, one 
may suggest the importance of the glucocorticoid system in maintaining the 
melanocytes and protecting them from potential autoimmunity, but nothing 
further.  
Cytokines have an important role in regulating the HPA axis. In the case of 
vitiligo, the expression pattern of pro- and anti-inflammatory cytokines has 
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altered. [36–38, 41] For example, the pro-inflammatory cytokine IL6, which 
increases the ICAM1 expression in melanocytes promoting melanocyte-
leukocyte interaction and thus the apoptosis of melanocytes [182]; TNFA, 
which activates apoptotic pathways potentially destroying melanocytes; and 
IL1, which stimulates the proliferation of CD4+ and CD8+ T cells and B cells. 
[36] IL1, IL6, and TNFA also stimulate each other’s expression. [22, 36, 182] 
The expression level of these three cytokines has increased in vitiligo patients. 
[22, 36, 182] All these cytokines stimulate the HPA axis; however, it is known 
that excessive activation of the classical HPA axis leads to immunosupression. 
[13, 18, 22, 182]  
Among IL10 family cytokines, the expression of the pro-inflammatory cyto-
kines IL19, which potentially stimulate apoptosis through IL6 and TNFA, and 
IL22, which initiates the innate immune system, has increased in patients’ 
blood. [195, 327, 328] There is no information about any associations between 
these two cytokines and HPA axis regulation; thus, they may potentially stimu-
late the HPA axis through IL6, TNFA, and other mechanisms. The expression 
of the anti-inflammatory cytokine IL10 decreased in patients. [41] IL10, which 
inhibits the synthesis of pro-inflammatory cytokines, such as TNFA, is an 
important regulator of the HPA axis. [329] In the classical HPA axis, IL10 
stimulates the production of CRH and ACTH, which may possibly be similar 
locally in the skin. [330] 
Interferons are also important in regulating the HPA axis. The level of 
IFNG, which is essential for activating both the adaptive and the innate immune 
systems, has increased in vitiligo patients’ skin. [242] It has been shown that it 
can inhibit and activate the HPA axis, depending on the concentration – higher 
levels stimulate the HPA axis. [331, 332] The pattern is similar in the case of 
IFNA and IFNB – the expression has increased in vitiligo patients, and they 
both activate ACTH and cortisol synthesis in the classical HPA axis. [333–335] 
Thus, assuming that in the classical and cutaneous HPA axis, the effects of dif-
ferent cytokines are similar, one might suggest that the IL-10 family cytokines, 
interferons, and other pro-inflammatory cytokines all support the elevated acti-
vation of the cutaneous HPA axis in the case of vitiligo pathogenesis.  
Dopamine is known to prevent excessive HPA axis activation during stress 
(in the rat brain). [14] In vitiligo patients’ skin, plasma, and urine, the dopamine 
level is elevated, possibly promoting the destruction of melanocytes. [34, 39, 
40, 264, 292, 293] We also demonstrated that several genes associated with the 
dopamine pathway, are expressed differently in vitiligo patients’ skin. Thus, if 
the dopamine effect on the cutaneous HPA axis is similar to the classical dopa-
mine system, contrary to cytokines, it seems to inhibit the cutaneous HPA axis.  
In vitiligo patients, the functioning of the cutaneous HPA axis (possibly the 
classical HPA axis, too) is somehow altered. Although the CRH system may 
have remained normal, the POMC system, which is essential for retaining 
melanogenesis active and melanocytes alive [162–166] is severely shifted – this 
pathway seems to be inhibited. According to the available data, the glyco-
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corticoids system appears to be functioning tolerably. The cytokines seem to 
activate the HPA axis in vitiligo patients and the dopamine seems to inhibit it. 
Thus, in vitiligo patients’ skin, the different mediators of the local HPA axis 
appear to have taken the system out of its ordinary course. The most important 
displacement, the melanocortin system, may potentially be the heart of this 
digression, and the activating and inhibiting agents may attempt to restore the 
normal state. 
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7. CONCLUSION  
In vitiligo patients, the function of the cutaneous HPA axis has deviated from 
its normal state. The main inducer appears to be the changes in the 
melanocortin system, and the activating (cytokines) and inhibiting (dopamine) 
agents may attempt to restore the normal state of skin homeostasis. 
 When evaluating the possible role of the CRH-POMC system and the 
associated systems (MCH, endogenous opioids) in vitiligo pathogenesis, 
we found the following results: 
 This study identified new genes, which may possibly be related to 
vitiligo pathogenesis – PNOC and its receptor OPRL1 are both 
upregulated in involved vitiligo skin compared to controls. Until now, 
there is no information about the POMC and PNOC derived peptides 
sharing their receptors with each other. The CRH-POMC system 
seems to have a major role in regulating different skin functions; it is 
highly likely that PNOC is also connected to this pathogenic network. 
 We were able to detect PMCH mRNA in whole skin biopsies, which 
has not been demonstrated before. We confirmed the previous results 
about the possible involvement of the MCH system in vitiligo 
pathogenesis – increased mRNA levels of PMCH in vitiligo skin and 
its receptor MCHR1 in uninvolved vitiligo skin may be associated 
with the POMC system antagonizing mechanism and lead to 
decreased melanogenesis and destruction of melanocytes. 
 Until now the possible associations between vitiligo and CRH and its 
receptors CRHR1 and CRHR2 have not been investigated. The 
present study did not establish any, direct associations between the 
CRH system and vitiligo pathogenesis.  
 When analysing different cytokines, their receptors, and a few other 
genes possibly related to the development, proliferation, and survival of 
melanocytes and regulation of melanogenesis, we demonstrated the fol-
lowing: 
 The present study found additional support that IL10 family cytokines 
and their receptors are important in vitiligo pathogenesis – there were 
significant changes in mRNA expression levels of IL20RB, IL22RA2, 
IL28A, and IL28RA in vitiligo patients’ skin and/or PBMCs compared 
to controls.  
 This study supported our previous findings about the possible 
involvement of IL22 in vitiligo – the decreased level of IL22RA2 in 
the active stage vitiligo skin is unable to bind enough IL22, which 
potentially leads to increased inflammation. 
 We found additional information that LPS stimulation has different 
effects on the expression of IL10 family cytokines in the PBMCs of 
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patients compared to controls. This could indicate changes in the 
innate immunity system in the case of vitiligo pathogenesis.  
 We found that MDM1 may be associated with vitiligo pathogenesis, 
which has not been implied before. The possible involvement of IFNA 
and IFNB in the induction and maintenance of vitiligo lesions was 
supported by the present study. The study supplied additional 
information to previous work by other research teams about the 
involvement of IFNG together with ICAM1 in vitiligo pathogenesis.  
 When evaluating the possible role of genes related to the dopamine path-
way and vitiligo pathogenesis, we found additional support that the 
dopamine pathway may have an essential role in vitiligo pathogenesis: 
 In addition to influencing skin processes through the melanocortin 
pathway, the dopamine pathway potentially acts directly as well. In 
addition to enzyme activity data, we now have evidence of mRNA 
and protein expression changes in vitiligo patients’ skin in the case of 
MAOA, MAOB, and DDC.  
 We demonstrated the changes in the expression pattern of D1-like 
family dopamine receptors in vitiligo patients’ skin and blood. 
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8. FUTURE PROSPECTS  
Our present studies are mostly based on on measuring the mRNA expression 
level of different genes in PBMCs and the skin. However, the mRNA profile 
does not necessarily reflect the protein levels. We need to conduct also protein 
studies for the IL10 family cytokines and their receptors and associated genes; 
also, the genes of the endogenous opioid system should be included.  
In the case of the endogenous opioids pathway, we need to observe the 
PENK gene and protein expression in the future; recently it has been shown to 
be associated with vitiligo pathogenesis. 
In dopamine pathway studies, we measured also the protein level of some 
genes in the skin and in blood sera. However, in the case of enzymes, the 
activity is also an essential indicator to consider. Thus, this could also be one of 
our future goals – to observe the activity of enzymes participating in the CRH-
POMC pathway, other endogenous opioids pathways, the dopamine pathway, 
and the associated pathways of IL10 family cytokines.  
We also would like to carry out some immunohistochemical studies with 
skin and blood cells from vitiligo patients and controls. It could provide 
additional information – in which cells exactly our study objects are expressed 
in different conditions.  
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10. SUMMARY IN ESTONIAN 
Tsütokiinide ja neuroendokriinse süsteemi  
osalemine vitiliigo patogeneesis 
Üldteoreetiline taust 
Nahk on keha suurim organ, mis koosneb kolmest kihist: epidermisest, dermi-
sest ja hüpodermisest. Nahk on barjääriks keskkonna ja organismi sisemuse 
vahel ning selle peamiseks funktsiooniks on säilitada kehas tasakaal erinevate 
sisemiste ja väliste faktorite mõjuväljas. Kuna nahas asuvad ka immuunrakud ja 
närvirakud, siis lisaks füüsilisele barjäärile kasutatakse tasakaalu säilitamiseks 
sekretoorset aktiivsust, naha immuunsüsteemi ja pigmendi tootmist, samuti 
vaskulaarseid ja mesenhümaalseid komponente dermisest. Neuroendokriinsetest 
telgedest üks olulisemaid süsteemse stressi vastuse andjatest on hüpotaalamuse-
hüpofüüsi-neerupealise telg (HPA telg), mis klassikaliselt koosneb CRH-
POMC-glükokortikoidide signaalirajast. Kuna nahk on võimeline tootma kõiki 
vajalikke mediaatoreid ja vastavaid retseptoreid, siis võib öelda, et eksisteerib 
lokaalne HPA telg. HPA telje funktsioneerimist ja aktiivsust reguleerivad eri-
nevad tsütokiinid ja neuromediaatorid, nagu IL1, IL6, TNFA, dopamiin, 
norepinefriin, serotoniin.  
Vitiliigo on idiopaatiline haigus, kus seni veel täpselt teadmata põhjustel 
hävinevad melanotsüüdid ja selle tagajärjel tekivad nahale pigmenditud laigud. 
Peamised teooriad on autoimmuunne, neuraalne ja biokeemiline hüpotees. 
Arvatakse ka, et vitiliigo on teatud ulatuses pärilik. Vitiliigo võib esineda sõltu-
mata soost, vanusest, rassist ning sageli koos teiste autoimmuunhaigustega. 
Patsiendid kannatavad psühholoogilise stressi all ja neil on suurenenud risk 
saada nahavähk.  
Siiani on näidatud, et paljud geenid, mis osalevad lokaalse HPA telje töös, 
on vitiliigohaigetel teisiti ekspresseerunud, võrreldes kontrollidega. Meie töö-
grupp on varem näidanud POMC süsteemi geenide ekspressiooni langemist 
vitiliigohaigete nahas (nii POMC kui ka retseptorgeenid), samuti IL10 tsüto-
kiinide perekonna geenide ekspressiooni muutusi (eelpõletikulise IL22, eel-
apoptootilise IL24 ja retseptorite alaühikute IL10RA ja IL10RB ekspressioon 
kasvanud). Lisaks on kirjandusest teada teiste põletikuliste tsütokiinide, nagu IL1, 
IL6, TNFA ning samuti dopamiini taseme tõus vitiliigohaigete nahas ja veres.  
 
Uurimustöö põhieesmärgid 
Peamine eesmärk oli saada lisainformatsiooni närvisüsteemi ja immuunsüteemi 
interaktsioonidest vitiliigohaigete nahas. Tahtsime hinnata endogeensete opioi-
dide, CRH, MCH, IL10 perekonna tsütokiinide, dopamiini raja ning nendega 
seotud radade võimalikku osalust vitiliigo patogeneesis. Kuna tõenäoliselt kõik 
need rajad osalevad naha HPA telje tegevuses, siis tahtsime hinnata muutusi 
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HPA telje töös vitiliigohaigetes, võrreldes kontrollidega. Selleks seadsime järg-
mised eesmärgid:  
 CRH-POMC süsteemi ja nendega seotud radade (MCH ja endogeensete 
opioidide süsteemi) analüüsimine vitiliigohaigete ja kontrollide nahas. 
Selleks analüüsiti 12 geeni mRNA ekspressiooni.  
 IL10 perekonna tsütokiinide ja teiste melanogeneesi ning melanotsüütide 
kasvu ja arenguga seotud geenide analüüs vitiliigohaigete nahas ja perifeerse 
vere mononukleaarsetes rakkudes (PBMC). Selleks mõõdeti 12 geeni 
mRNA ekspressiooni.  
 Dopamiini rajaga seotud geenide analüüsimine vitiliigohaigete veres ja nahas. 
Selleks uuriti 17 geeni mRNA ja valgu ekspressiooni nahas ja vereseerumis.  
 
Metoodika 
Kõigi uurimustöös osalenud vitiliigo patsientide haigusvormiks oli vitiligo vul-
garis ning kuus kuud enne vere ja nahaproovide kogumist ei saanud patsiendid 
ravi. Kontrollgrupis olevate indiviidide perekonnas pole teadaolevalt esinenud 
vitiliigot või teisi kroonilisi dermatoose. CRH-PMC süsteemi uuringus osales 
18 vitiliigo patsienti ja 14 kontrollindiviidi. Melanogeneesi ja melanotsüütide 
funktsioneerimisega seotud tsütokiinide (IL10 perekonna tsütokiinid ja seotud 
geenid) uurimustöös osales naha uuringus 15 patsienti ja 15 kontrollindiviidi 
ning vere uuringus 15 patsienti ja 17 kontrollindiviidi. Dopamiini raja töös 
osales naha mRNA uuringus 27 patsienti ja 20 kontrollindiviidi, naha valgu 
uuringus 6 patsienti ja 10 kontrollindiviidi ning vere valgu uuringus 14 patsienti 
ja 14 kontrollindiviidi.  
Naha biopsiatest ja PBMCdest mRNA ekspressiooni mõõtmiseks eraldati 
vastavatest proovidest totaalne RNA, millest sünteesiti cDNA, mida omakorda 
analüüsiti TaqMan- QRT-PCR meetodiga. Uuritavate geenide ekspressiooni 
normaliseerimisel kasutati koduhoidja geeni HPRT1. Kõiki proove analüüsiti 
neljas korduses ja omavahel võrreldi vitiliigohaigete kahjustatud ja kahjusta-
mata nahka ning kontrollindiviidide nahka, lisaks vitiliigohaigete ja kontrollide 
PBMCdest mõõdetud mRNA ekspressiooni tasemeid.  
Valgu ekspressiooni mõõtmiseks naha biopsia homogenaatidest ja vere 
seerumist kasutati kommertsiaalseid ELISA analüüsikomplekte (uuriti DDC, 
MAOA, MAOB, DRD1 ja DRD5 valgu taset). Omavahel võrreldi vitiliigo-
haigete kahjustatud ja kahjustamata nahka ning kontrollindiviidide nahka ning 
vitiliigohaigete ja kontrollide vereseerumeid.  
 
Tulemused 
CRH-POMC süsteemi geenide ekspressiooni profiil vitiliigohaigete 
nahabiopsiates 
PNOC ja selle retseptori OPRL1 mRNA ekspressioon oli vitiliigohaigete 
kahjustatud nahas vastavalt 2,99 ja 1,83 korda kõrgem kui kontrollide nahas 
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(mõlemal juhul P < 0,05). OPRL1 puhul oli ekspressioon kasvanud vaid sta-
biilse vitiliigo vormiga patsientidel – erinevus 2,43 korda (P < 0,01). PMCH 
ekspressioon oli kahjustamata nahas kasvanud 1,85 (P < 0,05) ja kahjustatud 
nahas 5,36 korda (P < 0,01), võrreldes kontrollide nahaga. MCHR1 tase oli 
vitiliigohaigete kahjustamata nahas 3,57 korda kõrgem kui kahjustatud nahas. 
PDYN, OPRK1, CRHR1, ATRN ja NURR1 ekspressiooni tasemed ei erinenud 
patsientidel ja kontrollidel. OPRD1, OPRM1 ja CRH mRNA tasemed olid liiga 
madalad usaldusväärse analüüsi teostamiseks.  
 
Melanotsüütide funktsiooni reguleerivate tsütokiinide mRNA ekspressiooni 
profiil vitiligohaigete nahabiopsiates ja perifeerse vere mononukleaarsetes 
rakkudes 
IL20RB mRNA ekspressioon oli vitiliigohaigete kahjustamata nahas kasvanud 
1,4 korda (P < 0,01), võrreldes kontrollidega. Stabiilse vitiliigoga patsientide 
kahjustatud nahas oli IL20RB tase kasvanud 1,5 korda (P < 0,05). IL20RB tase 
oli vitiliigohaigete veres kasvanud 32,3 korda (P < 0,001) ja koos LPS stimu-
latsiooniga 9,6 korda (P < 0,001). LPS stimulatsioon langetas IL20RB taset 
patsientide veres 4,3 korda (P < 0,001); seda ei esinenud kontrollide puhul. 
IL22RA2 mRNA ekspressioon oli patsientide kahjustamata nahas 1,5 korda 
(P < 0,05) kõrgem kui kontrollide nahas. Kahjustatud nahas oli tase langenud 
1,6 korda (P < 0,05), võrreldes kahjustamata nahaga – see efekt esines vaid 
aktiivse vitiliigoga patsientidel. PBMCdes oli IL22RA2 tase detekteerimise 
piiril ja usaldusväärset statistilist analüüsi ei saanud teostada. IL26 ekspressioon 
ei erinenud patsientide ja kontrollide nahas ning PBMCdes oli tase liiga madal 
usaldusväärse analüüsi läbiviimiseks. IL28A, IL28B ja IL29 nahas ning IL29 
tase PBMCdes oli liiga madal usaldusväärseks analüüsimiseks. IL28RA tase oli 
vitiliigohaigete kahjustamata nahas kasvanud 1,7 korda (P < 0,01), võrreldes 
kontrollidega. IL28A mRNA tase oli LPS stimulatsiooniga patsientide 
PBMCdes 1,7 korda madalam (P < 0,05) kui kontrollides. IL28B ja IL28RA 
tasemed ei erinenud patsientide ja kontrollide PBMCdes. MDM1 mRNA 
ekspressiooni tase oli 4,2 korda kõrgem (P < 0,001) patsientide kahjustamata 
nahas ja 3,0 korda kõrgem (P < 0,001) kahjustatud nahas, võrreldes kont-
rollidega. Veres oli MDM1 tase patsientide rakkudes LPS stimulatsioonita 1,7 
korda kõrgem (P < 0,01) ja LPS stimulatsiooniga 1,5 korda kõrgem (P < 0,01). 
IFNA1 mRNA ekspressiooni tase nahas oli liiga madal usaldusväärse analüüsi 
teostamiseks. Veres oli IFNA1 tase 4,8 korda kõrgem (P < 0,05) patsientide 
rakkudes, võrreldes kontrollidega. Stabiilse vormiga haigetel oli IFNA1 tase 
LPS stimulatsioonita 7,3 korda kõrgem (P < 0,05) ja LPS stimulatsiooniga 9,0 
korda (P < 0,01) kõrgem – sellist erinevust ei esinenud aktiivse vormiga 
haigetel. IFNB1 ekspressioon oli vitiliigohaigete kahjustamata nahas 4,5 korda 
kõrgem (P < 0,05) ja PBMCdes 2,9 korda kõrgem (P < 0,05), võrreldes 
kontrollidega. Stabiilse vormiga haigete PBMCdes oli LPS stimulatsioonite 
mRNA ekspressiooni taseme kasv 3,4 kordne (P < 0,01) ja LPS stimulat-
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siooniga 3,0 kordne (P < 0,05) – sellist erinevust ei esinenud aktiivse vormiga 
patsientide puhul. IFNG mRNA tase oli patsientide kahjustatud nahas 3,9 korda 
kõrgem (P < 0,05), võrreldes kontrollide nahaga. LPS stimulatsioonita oli IFNG 
tase kasvanud patsientide PBMCdes 3,5 korda (P < 0,01) ja LPS stimulat-
siooniga 3,3 korda (P < 0,01), võrreldes kontrollidega. ICAM1 tase oli pat-
sientide kahjustamata nahas 1,7 korda (P < 0,01) ja kahjustatud nahas 1,4 korda 
(P < 0,05) kõrgem kui kontrollide nahas. ICAM1 tase oli stabiilse vitiliigoga 
patsientide kahjustatud nahas langenud 1,7 korda (P < 0,01), võrreldes kahjusta-
mata nahaga – seda ei esinenud aktiivse vormi puhul. PBMCdes ICAM1 tase 
patsientides ja kontrollides ei erinenud.  
 
Dopamiini rajaga seotud geenide ekspressiooni profiil vitiliigohaigete 
nahabiopsiates ja vereseerumis 
PAH ja TH mRNA tase oli nahas liiga madal usaldusväärse analüüsi teosta-
miseks. PCD, DBH ja PMNT mRNA ekspressioon ei erinenud patsientide ja 
kontrollide nahas. DDC mRNA tase oli patsientide kahjustamata nahas 5,2 
korda (P < 0,05) ja kahjustatud nahas 7,6 korda (P < 0,05) madalam kui 
kontrollide nahas. GPX1 tase oli stabiilse vitiliigoga patsientide kahjustatud 
nahas 2,7 korda kõrgem (P < 0,05) kui kontrollide nahas ning stabiilse vormiga 
haigetel 2,7 korda kõrgem (P < 0,05) kui aktiivse vormiga haigete kahjustatud 
nahas. MAOA mRNA tase oli stabiilse vitiliigoga haigete kahjustamata nahas 
1,8 korda kõrgem (P < 0,05) kui kontrollide nahas. Kahjustatud nahas oli 
erinevus kontrollidega aktiivse vitiliigoga patsientidel 2,5 kordne (P 0,001) ja 
stabiilse vormiga haigetel 2,2 kordne (P < 0,05). MAOB ja COMT ekspressiooni 
tasemed ei erinenud patsientide ja kontrollide nahas. DRD1 ja DRD5 mRNA 
ekspressiooni tase oli vitiliigohaigete kahjustamata nahas kasvanud vastavalt 
4,2 (P < 0,001) ja 1,9 (P < 0,01) korda. Kahjustatud nahas oli DRD1 mRNA 
tase kasvanud 3,2 korda (P < 0,05). DRD2 tase ei erinenud patsientidel ja kont-
rollidel. DRD3 ja DRD4 ekspressiooni tase oli detekteerimise piiril ja usaldus-
väärset analüüsi ei saanud teostada. VMAT1 ja VMAT2 tasemed ei erinenud 
patsientidel ja kontrollidel.  
DDC valgu tase oli aktiivse vormiga haigetel kasvanud kahjustamata nahas 
2,7 korda (P < 0,05) ja kahjustatud nahas 1,8 korda (P < 0,05). MAOA valgu 
tase oli aktiivse vormiga patsientide kahjustamata nahas 2,8 korda (P < 0,05) ja 
kahjustatud nahas 1,8 korda (P < 0,05) kõrgem kui kontrollide nahas. MAOB 
valgu tase oli aktiivse vormiga patsientide kahjustamata nahas 2,7 korda 
(P < 0,05) ja kahjustatud nahas 2,0 korda (P < 0,05) kõrgem kui kontrollidel. 
DRD1 valgu tase oli aktiivse vormiga haigete kahjustamata nahas 2,6 korda 
kõrgem (P < 0,05) ja kahjustatud nahas 1,8 korda kõrgem (P < 0,05) kui kont-
rollide nahas. DRD5 valgu tase oli kasvanud aktiivse vitiliigoga patsientidel 3,0 
korda (P < 0,01) kahjustamata nahas ja 2,1 korda (P < 0,05) kahjustatud nahas, 
võrreldes kontrollidega.  
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Vereseerumis oli DDC, MAOA, MAOB ja DRD5 valgu tase patsientidel ja 
kontrollidel sarnane. DRD1 valgu tase oli patsientide seerumis 1,4 korda 
(P < 0,01) langenud, võrreldes kontrollidega.  
 
Järeldused 
Lokaalse HPA telje funktsioneerimine on vitiliigohaigete nahas oma normaal-
sest olekust kõrvale kaldunud. Peamiseks põhjuseks näivad olevat muutused 
melanokortiini rajas. HPA telje tööd aktiveerivate tsütokiinide ja inhibeeriva 
dopamiini süsteemi muutused võivad tuleneda katsest taastada normaalne 
olukord ja tasakaal.  
 Käesoleva uurimustööga leidsime, et PNOC ja OPRL1 geenide ekspres-
siooni taseme kasv vitiliigohaigete kahjustatud nahas võib viidata nende 
osalusele vitiligo patogeneesis.  
 Suutsime esmakordselt detekteerida naha biopsiates PMCH mRNA ekspres-
siooni. Kinnitasime varasemaid tulemusi MCH osalemisest vitiligo pato-
geneesis – MCH ja MCHR1 taseme kasv võib olla seotud POMC süsteemi 
inhibeerimisega, mis viib melanogeneesi vähenemiseni ja melanotsüütide 
hävinemiseni.  
 Oma tööga ei suutnud me leida otseseid seoseid CRH raja geenide ja vitiligo 
patogeneesiga.  
 Käesolev töö tõestas veelkord, et IL10 perekonna tsütokiinid on olulised 
vitiliigo patogeneesis – näitasime IL20RB, IL22RA2, IL28A ja IL28RA 
ekspressiooni muutusi vitiliigohaigete nahas ja/või veres. 
 Saime lisakinnitust IL22 olulisele rollile vitiliigo patogeneesis – tõenäoliselt 
ei suuda IL22RA2 vähenenud kogus siduda piisaval hulgal IL22, et vältida 
põletikulisi protsesse.  
 Tööga näitasime veelkord, et LPS stimulatsioon mõjub IL10 perekonna 
tsütokiinidele vitiliigohaigetes ja kontrollides erinevalt, mis võib viidata 
vitiliigohaigete kaasasündinud immuunsuses muutustele.  
 Näitasime esmakordselt MDM1 geeni võimalikku seotust vitiliigo pato-
geneesiga. Lisaks toetasime varasemaid uuringuid IFNA ja IFNB osalusest 
vitiliigo tekkes ja püsimises, samuti IFNG ja ICAM1 osalusest vitiliigo 
patogeneesis.  
 Käesolev töö andis lisakinnitust dopamiini raja võimalikule osalusele 
vitiliigo patogeneesis – võimalik, et lisaks tasakaalu mõjutamisele läbi 
melanokortiini raja võib dopamiin olukorda nahas ka otseselt muuta. Lisaks 
varasematele dopamiini raja ensüümide aktiivuse informatsioonile on meil 
nüüd olemas ka mRNA ja valgu ekspressiooni andmed. Lisaks näitasime 
D1-tüüpi dopamiini retseptorite perekonna geenide võimalikku osalust 
vitiliigo patogeneesis.  
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